CN118063537A - 定向淋巴的前药 - Google Patents
定向淋巴的前药 Download PDFInfo
- Publication number
- CN118063537A CN118063537A CN202410211373.7A CN202410211373A CN118063537A CN 118063537 A CN118063537 A CN 118063537A CN 202410211373 A CN202410211373 A CN 202410211373A CN 118063537 A CN118063537 A CN 118063537A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- acid
- self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940002612 prodrug Drugs 0.000 title claims abstract description 59
- 239000000651 prodrug Substances 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 99
- 229940079593 drug Drugs 0.000 claims abstract description 67
- 210000004324 lymphatic system Anatomy 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 177
- 239000000203 mixture Substances 0.000 claims description 117
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 114
- -1 cycloandrostanol Chemical compound 0.000 claims description 110
- 229960003604 testosterone Drugs 0.000 claims description 57
- 230000001926 lymphatic effect Effects 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 44
- 150000002632 lipids Chemical class 0.000 claims description 43
- 238000009472 formulation Methods 0.000 claims description 36
- 210000002751 lymph Anatomy 0.000 claims description 36
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 29
- 229960001736 buprenorphine Drugs 0.000 claims description 29
- 230000000968 intestinal effect Effects 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 239000008177 pharmaceutical agent Substances 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 21
- 239000012267 brine Substances 0.000 claims description 21
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 21
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 17
- 229930195729 fatty acid Natural products 0.000 claims description 17
- 229960000951 mycophenolic acid Drugs 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 238000010579 first pass effect Methods 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- 230000009885 systemic effect Effects 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 10
- 230000009286 beneficial effect Effects 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 229940011871 estrogen Drugs 0.000 claims description 6
- 239000000262 estrogen Substances 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 6
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims description 5
- 229960002669 albendazole Drugs 0.000 claims description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 5
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 claims description 5
- 229960000801 nelarabine Drugs 0.000 claims description 5
- 229940005483 opioid analgesics Drugs 0.000 claims description 5
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims description 5
- 229960005301 pentazocine Drugs 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- 206010058359 Hypogonadism Diseases 0.000 claims description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 4
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 229960001265 ciclosporin Drugs 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 229960004242 dronabinol Drugs 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 229940014456 mycophenolate Drugs 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- 229960001967 tacrolimus Drugs 0.000 claims description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 4
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 3
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 3
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 3
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 3
- 108010032976 Enfuvirtide Proteins 0.000 claims description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 3
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 3
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 3
- 229960004748 abacavir Drugs 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 229960004150 aciclovir Drugs 0.000 claims description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960000836 amitriptyline Drugs 0.000 claims description 3
- 229960001830 amprenavir Drugs 0.000 claims description 3
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 239000003430 antimalarial agent Substances 0.000 claims description 3
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 3
- 229960005370 atorvastatin Drugs 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 3
- 229950011318 cannabidiol Drugs 0.000 claims description 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 229960000590 celecoxib Drugs 0.000 claims description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001076 chlorpromazine Drugs 0.000 claims description 3
- 230000001268 conjugating effect Effects 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960004544 cortisone Drugs 0.000 claims description 3
- 229940111134 coxibs Drugs 0.000 claims description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- 229960003109 daunorubicin hydrochloride Drugs 0.000 claims description 3
- 229960005319 delavirdine Drugs 0.000 claims description 3
- 229960002656 didanosine Drugs 0.000 claims description 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229960003722 doxycycline Drugs 0.000 claims description 3
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960000366 emtricitabine Drugs 0.000 claims description 3
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims description 3
- 229960002062 enfuvirtide Drugs 0.000 claims description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 3
- 229960000556 fingolimod Drugs 0.000 claims description 3
- 229960002258 fulvestrant Drugs 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 229960003685 imatinib mesylate Drugs 0.000 claims description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 3
- 229960001936 indinavir Drugs 0.000 claims description 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 3
- 229960002418 ivermectin Drugs 0.000 claims description 3
- 229960002014 ixabepilone Drugs 0.000 claims description 3
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 3
- 229960001632 labetalol Drugs 0.000 claims description 3
- 229960001627 lamivudine Drugs 0.000 claims description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 3
- 229960000681 leflunomide Drugs 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
- 229960004844 lovastatin Drugs 0.000 claims description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
- 229960002237 metoprolol Drugs 0.000 claims description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- 229960005181 morphine Drugs 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- 229960000884 nelfinavir Drugs 0.000 claims description 3
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 3
- 229960001158 nortriptyline Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229960003171 plicamycin Drugs 0.000 claims description 3
- 229960005205 prednisolone Drugs 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 229960003712 propranolol Drugs 0.000 claims description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims description 3
- 229960002814 rilpivirine Drugs 0.000 claims description 3
- 229960000311 ritonavir Drugs 0.000 claims description 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 3
- 229960002052 salbutamol Drugs 0.000 claims description 3
- 229960001203 stavudine Drugs 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 3
- 229960001940 sulfasalazine Drugs 0.000 claims description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960004556 tenofovir Drugs 0.000 claims description 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 3
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 3
- 229960005026 toremifene Drugs 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- 229960000523 zalcitabine Drugs 0.000 claims description 3
- 229960002555 zidovudine Drugs 0.000 claims description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 3
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims description 2
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims description 2
- 206010065553 Bone marrow failure Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010009126 Chronic respiratory failure Diseases 0.000 claims description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 229960003305 alfaxalone Drugs 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002448 dasatinib Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 229960005304 fludarabine phosphate Drugs 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims description 2
- 229960004710 maraviroc Drugs 0.000 claims description 2
- 230000009245 menopause Effects 0.000 claims description 2
- 229960004570 oxprenolol Drugs 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 201000004193 respiratory failure Diseases 0.000 claims description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims 1
- 102000000521 Immunophilins Human genes 0.000 claims 1
- 108010016648 Immunophilins Proteins 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229960001215 bendamustine hydrochloride Drugs 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 229960003404 mexiletine Drugs 0.000 claims 1
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims 1
- 229960002110 vincristine sulfate Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 105
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 78
- 230000032258 transport Effects 0.000 description 52
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 49
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 41
- 238000005160 1H NMR spectroscopy Methods 0.000 description 39
- 230000002829 reductive effect Effects 0.000 description 38
- 241000700159 Rattus Species 0.000 description 30
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 27
- 238000010898 silica gel chromatography Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 238000000746 purification Methods 0.000 description 24
- 150000002148 esters Chemical class 0.000 description 23
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 22
- 229960002073 sertraline Drugs 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- 239000012043 crude product Substances 0.000 description 19
- 125000005647 linker group Chemical group 0.000 description 19
- 238000005259 measurement Methods 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 230000001839 systemic circulation Effects 0.000 description 17
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 15
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 15
- 229940125797 compound 12 Drugs 0.000 description 15
- 125000005456 glyceride group Chemical group 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000012453 sprague-dawley rat model Methods 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000004094 surface-active agent Substances 0.000 description 14
- 150000003626 triacylglycerols Chemical class 0.000 description 14
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 229960000746 testosterone undecanoate Drugs 0.000 description 13
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 150000001241 acetals Chemical class 0.000 description 12
- 238000006460 hydrolysis reaction Methods 0.000 description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000003379 elimination reaction Methods 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- 229940088679 drug related substance Drugs 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 9
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 9
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 9
- 229940126657 Compound 17 Drugs 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229940126086 compound 21 Drugs 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 230000009977 dual effect Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 210000003563 lymphoid tissue Anatomy 0.000 description 8
- 238000003305 oral gavage Methods 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000001384 succinic acid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 7
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 102000019280 Pancreatic lipases Human genes 0.000 description 6
- 108050006759 Pancreatic lipases Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 238000013103 analytical ultracentrifugation Methods 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 229940125758 compound 15 Drugs 0.000 description 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 6
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 229940116369 pancreatic lipase Drugs 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 6
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- DFATXMYLKPCSCX-UHFFFAOYSA-N 3-methylsuccinic anhydride Chemical compound CC1CC(=O)OC1=O DFATXMYLKPCSCX-UHFFFAOYSA-N 0.000 description 5
- DJYSRLXNZCKPPY-UHFFFAOYSA-N 4-[1,3-di(hexadecanoyloxy)propan-2-yloxy]-3-methyl-4-oxobutanoic acid Chemical compound C(CCCCCCCCCCCCCCC)(=O)OCC(COC(CCCCCCCCCCCCCCC)=O)OC(C(CC(=O)O)C)=O DJYSRLXNZCKPPY-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 102100022119 Lipoprotein lipase Human genes 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 150000005690 diesters Chemical class 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- 210000001365 lymphatic vessel Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229940093609 tricaprylin Drugs 0.000 description 5
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 108010004103 Chylomicrons Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007957 coemulsifier Substances 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 230000002366 lipolytic effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- XJMMNTGIMDZPMU-UHFFFAOYSA-N 3-methylglutaric acid Chemical compound OC(=O)CC(C)CC(O)=O XJMMNTGIMDZPMU-UHFFFAOYSA-N 0.000 description 3
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 3
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000043296 Lipoprotein lipases Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical group CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960003660 sertraline hydrochloride Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- YBYUQHCVMYVBLL-UHFFFAOYSA-N 2-(methoxymethoxy)acetic acid Chemical compound COCOCC(O)=O YBYUQHCVMYVBLL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- WXUAQHNMJWJLTG-UHFFFAOYSA-N 2-methylbutanedioic acid Chemical compound OC(=O)C(C)CC(O)=O WXUAQHNMJWJLTG-UHFFFAOYSA-N 0.000 description 2
- RGMSBDCQLRJNSH-UHFFFAOYSA-N 4-oxo-4-propan-2-yloxybutanoic acid Chemical compound CC(C)OC(=O)CCC(O)=O RGMSBDCQLRJNSH-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 102000012214 Immunoproteins Human genes 0.000 description 2
- 108010036650 Immunoproteins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910007926 ZrCl Inorganic materials 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- CGLRXKACBSXHIU-UHFFFAOYSA-N chloromethyl carbamate Chemical compound NC(=O)OCCl CGLRXKACBSXHIU-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 2
- 229960000928 clofarabine Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940087068 glyceryl caprylate Drugs 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000008173 hydrogenated soybean oil Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940049918 linoleate Drugs 0.000 description 2
- 229940040461 lipase Drugs 0.000 description 2
- 229960004525 lopinavir Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- VVSASNKOFCZVES-UHFFFAOYSA-N 1,3-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CN1C(=O)CC(=O)N(C)C1=O VVSASNKOFCZVES-UHFFFAOYSA-N 0.000 description 1
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- USPSDZQQNLMVMK-UHFFFAOYSA-N 1-Monolinolein Natural products CCCCCC=CC=CCCCCCCCC(=O)OCC(O)CO USPSDZQQNLMVMK-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- JIMZJGNNRSCEFH-UHFFFAOYSA-N 1-chloroethyl carbamate Chemical compound CC(Cl)OC(N)=O JIMZJGNNRSCEFH-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OUUCZGCOAXRCHN-UHFFFAOYSA-N 1-hexadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC OUUCZGCOAXRCHN-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LIJLYNWYKULUHA-UHFFFAOYSA-N 2-chloroethyl carbamate Chemical compound NC(=O)OCCCl LIJLYNWYKULUHA-UHFFFAOYSA-N 0.000 description 1
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- RXJJIFUOUWVKTA-UHFFFAOYSA-N 2-methyl-4-oxobutanoic acid Chemical compound OC(=O)C(C)CC=O RXJJIFUOUWVKTA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- XIIQDZOQBSLDBF-UHFFFAOYSA-N 4-[1,3-di(hexadecanoyloxy)propan-2-yloxy]-4-oxobutanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCC(O)=O)COC(=O)CCCCCCCCCCCCCCC XIIQDZOQBSLDBF-UHFFFAOYSA-N 0.000 description 1
- SEGYOKHGGFKMCX-UHFFFAOYSA-N 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]-1-piperidinecarboxylic acid (4-nitrophenyl) ester Chemical compound C=1C=C2OCOC2=CC=1C(C=1C=C2OCOC2=CC=1)(O)C(CC1)CCN1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 SEGYOKHGGFKMCX-UHFFFAOYSA-N 0.000 description 1
- XIBPCLQLEGQADN-UHFFFAOYSA-N 4-acetyloxy-4-oxobutanoic acid Chemical compound CC(=O)OC(=O)CCC(O)=O XIBPCLQLEGQADN-UHFFFAOYSA-N 0.000 description 1
- WNXNUPJZWYOKMW-UHFFFAOYSA-N 5-bromopentanoic acid Chemical compound OC(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JFLRKDZMHNBDQS-UCQUSYKYSA-N CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C Chemical compound CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C JFLRKDZMHNBDQS-UCQUSYKYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062023 Intestinal cyst Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002507 Poloxamer 124 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000005930 Spinosad Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 210000003892 absorptive cell Anatomy 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000007936 buccal or sublingual tablet Substances 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- CVASMYWHWRNWOX-UHFFFAOYSA-N chloro methyl carbonate Chemical compound COC(=O)OCl CVASMYWHWRNWOX-UHFFFAOYSA-N 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 125000005240 diheteroarylamino group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000001077 lymphatic endothelium Anatomy 0.000 description 1
- 230000003692 lymphatic flow Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 description 1
- 229960003868 paraldehyde Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229940093448 poloxamer 124 Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- RTVVXRKGQRRXFJ-UHFFFAOYSA-N sodium;2-sulfobutanedioic acid Chemical compound [Na].OC(=O)CC(C(O)=O)S(O)(=O)=O RTVVXRKGQRRXFJ-UHFFFAOYSA-N 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 229940014213 spinosad Drugs 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940093633 tricaprin Drugs 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 229940081852 trilinolein Drugs 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 229940124024 weight reducing agent Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0029—Ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
- C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/43—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/30—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0025—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
Abstract
本发明涉及定向淋巴的前药和它们的用途,该前药化合物促进药用物质转运至淋巴***且随后增强母体药物的释放。
Description
本申请是申请号为201680061468.9、申请日为2016年9月8日、发明名称为“定向淋巴的前药”的专利申请的分案申请。
技术领域
本发明涉及前药形式的化合物,特别涉及促进药用物质转运至淋巴***且随后增强母体药物释放的化合物。
背景技术
淋巴***由紧邻血管***分布在***的导管、结节和淋巴组织的特化网状结构组成。淋巴***在免疫应答、体液平衡、营养物吸收、脂质稳态和肿瘤转移中发挥众多关键作用。由于淋巴***的独特解剖学和生理学特征,靶向递药至淋巴***和通过淋巴***靶向递药已被建议为改善药物动力学和药效学特性的手段。淋巴药物转运具有通过避免首过代谢提高口服生物利用度、改变***药物处置和增强对淋巴或淋巴细胞介导的病理现象(例如淋巴瘤、白血病、淋巴肿瘤转移、自身免疫疾病、淋巴停留感染和移植体排斥)的效能的潜能。
为了使药物接近肠淋巴,它们必须首先结合肠淋巴脂蛋白,该脂蛋白响应脂质吸收而在肠吸收细胞(肠囊肿)中组装。与这些脂蛋白的结合随后促进药物转运入淋巴,因为它们的尺寸阻碍跨过消耗小肠的内衬毛细血管的血管内皮的便利扩散。相反,这些大胶体结构进入淋巴毛细管,因为淋巴内皮明显比血管内皮更具有渗透性。从历史上看,具有高淋巴转运的药物具有高度亲脂性,以便促进与脂蛋白的物理结合(通常,但不排它地,log D>5,且在长链甘油三酯中的溶解度>50mg/g)。因此,药物的高度亲脂性类似物被设想为促进淋巴药物转运的一种方式。然而,母体药物的化学修饰可能导致作用强度降低,并且在许多情况中,亲脂性的显著增加与毒性增加相关联。
亲脂性前药形式的化合物提供了一种暂时增加药物化合物的亲脂性和的脂蛋白亲和力(由此增加淋巴靶向)的手段。通过淋巴***转运,前药最终恢复成母体药物,以便在其靶位点上具有活性。
存在几种探索药物的简单脂族酯类用作定向淋巴的前药的潜能的研究。十一酸睾酮提供了一个采用该方法的上市销售的化合物的实例。经口施用后,睾酮在其首次通过肝时几乎全部被完全代谢,结果它具有最小生物利用度。睾酮的十一酸酯使小比例的被吸收的剂量重新定向进入淋巴***,由此避免肝脏首过代谢并且增加睾酮的口服生物利用度。然而,这种方法仍然是非常低效的,且认为经口施用所述十一酸酯后睾酮的生物利用度<5%。
促进淋巴药物转移的另一种机制是使用前药,该前药结合到与膳食脂质的吸收、转运和处置相关的内源性途径。用作前药的膳食脂质的一个实例是甘油三酯。药物-脂质缀合物的实例已被记录在大量在先的出版物中,其中母体药物包含可利用的羧酸基团且直接与甘油酯骨架缀合(Paris,G.Y.等人,J.Med.Chem.1979,22,(6),683-687;GarzonAburbeh,A.等人,J.Med.Chem.1983,26,(8),1200-1203;Deverre,J.R.等人,J.Pharm.Pharmacol.1989,41,(3),191-193;Mergen,F.等人,J.Pharm.Pharmacol.1991,43,(11),815-816;Garzon Aburbeh,A.等人,J.Med.Chem.1986,29,(5),687-69;以及Han,S.等人J.Control.Release 2014,177,1-10)。
在其它实例中,将短的连接基用于促进药物-甘油三酯缀合,其中药物不含可利用的羧酸(Scriba,G.K.E.,Arch.Pharm.(Weinheim)。1995,328,(3),271-276;以及Scriba,G.K.E.等人,J.Pharm.Pharmacol.1995,47,(11),945-948)。这些药物-脂质缀合物使用琥珀酸促进与可利用的羟基官能团的缀合。然而,文献教导这种结构根本无用,例如,Scriba检查了睾酮-琥珀酸-甘油酯脂质缀合物的体外水解,并且得出结论“本研究中通过化学水解、血浆酯酶催化的水解和脂肪酶介导的水解从前药中仅极为缓慢地释放睾酮…因此,睾酮缀合物看起来是递送类固醇的不良前药。”
其它文献使用与甘油酯醚键合以及与药物酯键合(Sugihara,J.等人,J.Pharmacobiodyn.1988,11,(5),369-376;以及Sugihara,J.等人,J.Pharmacobiodyn.1988,11,(8),555-562)。这些论文的作者清楚地描述,甘油与正烷基链之间的醚键以及正烷基链与药物之间的酯键对于药物的化学修饰似乎是必需的。然而,本发明的发明人发现,实际上醚键是起反作用的,无法实现显著的淋巴转运。
因此,对于开发新的脂质-药用物质缀合物存在需求,所述的缀合物有利于药用物质稳定地转运至肠淋巴并且易于复原为母体药剂以便有效。
发明内容
目前已经发现,自消除(self-immolative)基团和某些连接基用于将药用物质连接至甘油三酯单元的应用为所得到的脂质-药用物质缀合物提供了最佳药物动力学特性。
因此,在一个方面,本发明提供式(I)的化合物:
其中
R1和R2独立地表示H或C2-C28脂肪酸的残基;
-X-选自-O-、-NH-和-S-;
表示药用物质的残基;
-L-是-OC(O)-或-X’-;
当-L-是-OC(O)-时,-Y-表示任选被取代的-C1-C20烷基C(O)OCH2-、-C2-C20烯基C(O)OCH2-或-C2-C20炔基C(O)OCH2-基团;其中烷基、烯基或炔基基团中的碳原子的一个或多个可以被NH、S、O、C5-C8芳族或脂族环状基团或者C5-C8芳族或脂族杂环基团替代,条件是所述烷基、烯基或炔基基团不超过相当于直链C20烷基基团的长度;或者
当-L-是-X’-时,-Y-表示任选被取代的-C1-C2烷基C(O)R3-基团或-C2烯基C(O)R3-或-C2炔基C(O)R3-基团;
R3是自消除基团;
X’是O、S、N(R4)或N(H)S(O)2;
R4是H或C1-C4烷基;或者
其药学上可接受的盐。
在另一方面,本发明提供式(V)表示的式(I)的化合物:
其中R1、R2和-X-如对式(I)所定义;
R5和R6独立地选自氢和C1-C4烷基;且
R3是自消除基团;或者
其药学上可接受的盐。
在另一方面,本发明提供一种治疗或预防疾病或障碍的方法,在所说的疾病或障碍中增加的睾酮水平是有益的,该方法包括对有此需要的受试者施用治疗有效量的式(V)的化合物。
在另一方面,本发明提供式(V)的化合物在制备用于治疗或预防疾病或障碍的药剂中的用途,在所说的疾病或障碍中增加的睾酮水平是有益的。
在另一方面,本发明提供式(V)的化合物,其用于治疗或预防疾病或障碍,在该疾病或障碍中增加的睾酮水平是有益的。
在另一方面,本发明提供一种促进药用物质的淋巴转运和***释放的方法,该方法包括使式(VI)的前药残基或其药学上可接受的盐与药用物质缀合:
其中
R1和R2独立地表示H或C2-C28脂肪酸的残基;
-X-选自-O-、-NH-和-S-;
当-L-是-X’-时,-Y-表示任选被取代的-C1-C2烷基C(O)R3-基团或-C2烯基C(O)R3-或-C2炔基C(O)R3-基团;
R3是自消除基团;以及
表示连接基与药物活性剂缀合的点。
对于本领域技术人员而言,结合所附的实施例和权利要求书阅读下文的详细描述时,本发明的这些和其它方面将变得更加显见。
附图说明
图1:十二指肠内输注睾酮、十一烷酸睾酮(TU)、化合物21、化合物12、化合物13/14、化合物15、化合物17和化合物19后在麻醉的肠系膜***插套管的雌性SD大鼠中总的睾酮相关衍生物的蓄积淋巴转运(所施用剂量的%)与时间的关系的图解表示。
图2:对有意识的颈动脉插套管的雌性SD大鼠经口管饲睾酮、十一烷酸睾酮(TU)、化合物12、化合物15、化合物16、化合物17、化合物18、化合物20和化合物21后剂量归一化睾酮血浆浓度的图解表示。
图3:对有意识的颈动脉插套管的雌性SD大鼠经口管饲睾酮、十一烷酸睾酮(TU)、化合物12、化合物13、化合物13/14、化合物18和化合物19后剂量归一化睾酮血浆浓度的图解表示。
图4:十二指肠内输注SER盐酸盐(SER.HCl)和化合物3后在麻醉的肠系膜***插套管的雄性SD大鼠中总的舍曲林(SER)相关衍生物的蓄积淋巴转运(所施用剂量的%)与时间的关系的图解表示。
图5:经口管饲SER盐酸盐(SER.HCl)、化合物1、化合物2和化合物3后剂量归一化舍曲林(SER)血浆浓度的图解表示。
图6:十二指肠内输注BUP、化合物6和化合物7后在麻醉的肠系膜***插套管的雄性SD大鼠中总的丁丙诺啡(BUP)相关衍生物的蓄积淋巴转运(所施用剂量的%)与时间的关系的图解表示。
图7:经口管饲BUP、化合物5、化合物6和化合物7后剂量归一化丁丙诺啡(BUP)血浆浓度的图解表示。
图8:十二指肠内输注MPA、化合物10和化合物11后在麻醉的肠系膜***插套管的雄性SD大鼠中总的麦考酚酸(MPA)相关衍生物的蓄积淋巴转运(所施用剂量的%)与时间的关系的图解表示。
图9:与猪胰脂肪酶一起体外温育过程中化合物12、化合物13/14、化合物15、化合物16、化合物17、化合物20和化合物21的单酸甘油酯形式的稳定性特征的图解表示。
图10:MPA从1,3-二棕榈酰基甘油麦考酚酸酯(MPA-TG)、化合物10和化合物11中释放的图解表示。
具体实施方式
当前药策略用于药物开发领域以改善药物动力学特性时,通常预期前药通过非特异性降解或酶介导的生物转化复原为母体化合物,然后表现出生物活性。本发明公开了基于修饰的甘油酯的化合物,它们能够促进药用物质的淋巴转运并且改善所述化合物复原为活性药用物质。
膳食脂质,例如甘油三酯类应用独特的代谢途经以获得进入淋巴(并且最终进入体循环),其完全不同于其它营养物(例如蛋白质和碳水化合物)的代谢途经。在摄入后,膳食甘油三酯类被体腔脂肪酶水解,每个甘油三酯分子释放一个单酸甘油酯和两个脂肪酸。该单酸甘油酯和两个脂肪酸随后被吸收入肠细胞,在那里它们被重新酯化成甘油三酯类。
再合成的甘油三酯类被组装成肠脂蛋白(主要是乳糜微粒)且由此形成的乳糜微粒从肠细胞胞吐出来,且随后获得优先进入肠***。在***内,乳糜微粒形式的脂质通过一系列毛细血管、结节和输送管排出,最终在左锁骨下静脉和颈内静脉的连接处排空进入体循环。在进入血液循环后,乳糜微粒中的甘油三酯类优先和有效地被具有高脂蛋白脂肪酶表达的组织(例如脂肪组织、肝和潜在的某些类型的肿瘤组织)吸收。
预期脂质模拟化合物与天然甘油三酯具有类似的行为并且被转运至淋巴***和通过淋巴***,然后到达体循环。按照这种方式,母体药用物质的药物动力学和药效学特性可以***纵以增强进入淋巴和淋巴组织,由此通过避免首过代谢提高口服生物利用度(和潜在地肠流出)。脂质模拟化合物还可以促进药物靶向至淋巴、***和淋巴组织内的部位和高脂质利用和脂蛋白脂酶表达的部位,例如脂肪组织、肝和一些肿瘤。
经由体循环转运后易于转化成母体药物的脂质化前药降低了胃肠(GI)道中的游离药物浓度,这可以在减少胃肠刺激、掩蔽味道、促进药物在肠胆汁盐微团中增溶方面(归因于与内源性单酸甘油酯类的类似性)和提高被动膜渗透性方面(通过增加亲脂性)提供益处。脂质化前药还促进在包含单独的脂质或脂质与表面活性剂和/或助溶剂的混合物的脂质载体中溶解,并且这样做使得能以比母体药物可能可行的剂量更大的剂量以药物溶液施用。
本发明的发明人令人惊奇地发现,可以修饰将药用物质连接至甘油酯单元的药物-甘油酯缀合物的部分,以改善药物-甘油酯缀合物在GI道中的稳定性,促进转运至肠淋巴,且最终促进药用物质从药用物质-甘油酯前药中释放。因此,通过改变将药用物质连接至甘油酯单元的“连接基”,对于所得到的化合物可以实现最佳的药物动力学特性。
本发明人已经发现,即使当连接基是短链连接基(即,如先前报道的琥珀酸),在药用物质与甘油酯单元之间的连接基上结合自消除基团也导致改善的药物***释放和***暴露。自消除基团的结合增强了药用物质在体循环中的释放。虽然自消除基团可能会减少淋巴的药物转运,但首次发现,即使在淋巴转运减少的情况下,***性药物暴露得到增强,这可能是由于体循环中药物释放的增强所致。进一步发现,自消除基团与甘油酯单元之间的连接基上碳原子的甲基取代可以用于增加在胃肠道中的稳定性,增加淋巴转运并且仍然在体循环中保持良好的转化。
在本说明书中,应用了本领域技术人员众所周知的许多术语。尽管如此,为了清楚目的,将定义许多术语。
在本说明书中,除非另有定义,否则术语“任选被取代的”是指基团可以进一步被一个或多个基团取代,也可以不被这些基团取代,所述基团选自羟基、烷基、烷氧基、烷氧基羰基、烯基、烯氧基、炔基、炔氧基、氨基、氨基酰基、硫代、芳基烷基、芳基烷氧基、芳基、芳氧基、酰基氨基、羧基、氰基、卤素、硝基、磺基、膦酰基、磷酰基氨基、膦基、杂芳基、杂芳氧基、杂环基、杂环氧基、三卤代甲基、五氟乙基、三氟甲氧基、二氟甲氧基、三氟甲硫基、三氟乙烯基、一烷基氨基和二烷基氨基、一(取代的烷基)氨基和二(取代的烷基)氨基、一芳基氨基和二芳基氨基、一杂芳基氨基和二杂芳基氨基、杂环基一和二杂环基、氨基和具有选自烷基、芳基、杂芳基和杂环基的不同取代基的不对称二取代的胺类。
如本申请中所用,单独使用或在复合措词中使用的术语“烷基”表示直链或支链烷基。前缀例如“C2-C20”用于表示烷基内的碳原子数(在这种情况中为2-20个)。直链和支链烷基的实例包括甲基、乙基、正丙基、异丙基、正丁基、仲丁基、叔丁基、正戊基、己基、庚基、5-甲基庚基、5-甲基己基、辛基、壬基、癸基、十一基、十二烷基和二十二烷基(C22)。
如本申请中所用,单独使用或在复合措词中使用的术语“烯基”表示包含至少一个碳-碳双键的直链或支链烃残基,包括上文所定义的烯烃类单不饱和烷基、二不饱和烷基或多不饱和烷基。优选地,烯基是直链烯基。前缀例如“C2-C20”用于表示烯基内的碳原子数(在这种情况中为2-20个)。烯基的实例包括乙烯基、烯丙基、1-甲基乙烯基、丁烯基、异丁烯基、3-甲基-2-丁烯基、1-戊烯基、1-己烯基、3-己烯基、1-庚烯基、3-庚烯基、1-辛烯基、1-壬烯基、2-壬烯基、3-壬烯基、1-癸烯基、3-癸烯基、1,3-丁二烯基、1,4-戊二烯基、1,3-己二烯基、1,4-己二烯基和5-二十二烯基(C22)。
如本申请中所用,单独使用或在复合措词中使用的术语“炔基”表示包含至少一个碳-碳三键的直链或支链烃残基。优选地,炔基是直链炔基。前缀例如“C2-C20”用于表示烯基内的碳原子数(在这种情况中为2-20个)。
如本申请中所用,单独使用或在复合措词中使用的术语例如“杂环”或“杂环基”表示饱和、部分不饱和或完全不饱和单环、双环或稠合多环环系,其包含至少一个选自氮、硫和氧的杂原子。前缀例如“C5-C8”用于表示该基团环状部分内的碳原子数(在这种情况中为5-8个)。适合的杂环取代基的实例包括,但不限于吡咯、呋喃、苯并呋喃、苯并噻唑、咪唑、苯并咪唑、咪唑啉、吡唑、吡唑啉、***、唑、/>唑啉、异/>唑、异/>唑啉、呋咱、/>二唑、哌啶、吡啶、嘧啶、哒嗪和吡嗪,它们各自可以进一步被1-3个取代基取代。
如本申请中所用,术语例如“芳基”或“芳族环状基团”表示任意单核或多核的、缀合的或稠合的芳族烃基环系的残基。前缀例如“C5-C8”用于表示芳基环状部分内的碳原子数(在这种情况中为5-8个)。芳基的实例包括苯基(单核)、萘基(稠合的多核)、联苯基(缀合的多核)和四氢萘基(稠合的多核)。
如本申请中所用,术语“连接基”表示对于如本申请中所述的式(I)的化合物而言从“X”到“L”的化合物部分,其使药用物质连接至甘油酯单元。
如本申请中所用,术语“自消除基团”定义一种化学部分,其与所述的连接基形成易断裂的键,并与药用物质形成稳定的键,其中与药用物质的键在连接基裂解时变得不稳定。自消除基团的实例包括,但不限于乙缩醛自消除基团、羧基乙缩醛自消除基团、羧基(甲基乙缩醛)自消除基团、对羟基苄基羰基自消除基团、翻转酯自消除基团和三甲基锁自消除基团。许多其它适合的自消除基团在本领域中是已知的,例如C.A.Blencowe等人,Polym.Chem.2011,2,773-790和F.Kratz等人在ChemMedChem.2008,3(1),20-53中所述。
如本申请中所用,术语“药用物质”表示任意药物活性剂或成像(造影)剂,其将得益于通过肠淋巴***转运,例如以避免首过代谢或用于在淋巴***内靶向递送。
适合的药物活性剂的实例包括,但不限于睾酮、麦考酚酸(MPA)、丁丙诺啡、***类(***)、阿片类例如***、四氢***酚(THC)、***二酚、美托洛尔、雷洛昔芬、阿法沙龙、他汀类例如阿托伐他汀、喷他佐辛、***、L-DOPA、利多卡因、氯丙嗪、舍曲林、阿米替林、去甲替林、喷他佐辛,三***酯、氧烯洛尔、拉贝洛尔、沙丁胺醇、环硫雄醇、美法仑、洛伐他汀、非甾类抗炎药(NSAIDS,例如阿司匹林、布洛芬、萘普生)、COX-2抑制剂(例如塞来昔布)、皮质类固醇抗炎药(例如***龙、***、***)、抗疟药(例如羟氯喹)、亚硝基脲类、甲氨蝶呤、更生霉素、蒽环类(例如柔红霉素)、丝裂霉素C、博来霉素、光辉霉素、作用于抑免蛋白的药物(例如环孢素、他克莫司、西罗莫司)、柳氮磺吡啶、来氟米特、麦考酚酸酯、阿片样物质、芬戈莫德、多球壳菌素、苯丁酸氮芥、多柔比星、奈拉滨、可的松、***、***、普拉曲沙、长春碱、硼替佐米、奈拉滨、盐酸柔红霉素、氯法拉滨、阿糖胞苷、达沙替尼、甲磺酸伊马替尼、盐酸普纳替尼、硫酸长春新碱、盐酸苯达莫司汀、磷酸氟达拉滨、波舒替尼、尼洛替尼、美琥他辛、卡培他滨、紫杉醇、吉西他滨、氟维司群、他莫昔芬、拉帕替尼、托瑞米芬、伊沙匹隆、艾立布林、阿苯达唑、伊维菌素、乙胺嗪、阿苯达唑、多西环素、氯生太尔、马拉韦罗、恩夫韦肽、脱氧胸腺嘧啶核苷、齐多夫定、司他夫定、去羟肌苷、扎西他滨、阿巴卡韦、拉米夫定、恩曲他滨、替诺福韦、地拉韦啶、利匹韦林、拉替拉韦、艾维雷韦、洛匹那韦、茚地那韦、奈非那韦、氨普那韦、利托那韦、阿昔洛韦和药物活性肽类。
适合的成像剂的实例包括,但不限于,荧光团,例如用于荧光显微镜检查术的或用于体内成像的其中荧光团在红外范围内具有发射光谱的Alexa Fluor系列的光学成像探针;可以用于正电子发射断层摄影术(PET)的γ-发射体,例如氟脱氧葡萄糖或螯合剂,以便螯合磁共振成像探针,例如钆或铁。
为避免任何疑问,涉及“相当于直链C20烷基基团的长度”是指20个单独键合的碳原子理论上跨越的长度。
在本发明的一些优选的实施方案中,以及关于通式(I)或(II),如下定义中的一个或多个适用:
a)R1和R2独立地表示H或C2-C28脂肪酸的残基。
b)R1表示H,且R2表示C2-C28脂肪酸的残基。
c)R2表示H,且R1表示C2-C28脂肪酸的残基。
d)R1和R2各自表示棕榈酸。
e)-X-是-O-。
f)-X-是-NH-。
g)-X-是-S-。
h)-L-是-OC(O)-。
i)当-L-是-OC(O)-时,-Y-表示任选被取代的-C1-C20烷基C(O)OCH2-、-C2-C20烯基C(O)OCH2-或-C2-C20炔基C(O)OCH2-基团;其中烷基、烯基或炔基基团上的碳原子的一个或多个可以被NH、S、O、C5-C8芳族或脂族环状基团或者C5-C8芳族或脂族杂环基团替代,条件是所述烷基、烯基或炔基基团不超过相当于直链C20烷基基团的长度。
j)-Y-表示-C1-C20烷基C(O)OCH2-、-C2-C20烯基C(O)OCH2-或-C2-C20炔基C(O)OCH2-基团,其任选被烷基取代。
k)-Y-表示-C1-C20烷基C(O)OCH2-、-C2-C20烯基C(O)OCH2-或-C2-C20炔基C(O)OCH2-基团,其任选被甲基取代。
l)-L-是-X’-。
m)-Y-表示任选被取代的-C1-C2烷基C(O)R3-基团或-C2烯基C(O)R3-或-C2炔基C(O)R3-基团。
n)-Y-表示任选被烷基取代的-C1-C2烷基C(O)R3-基团。
o)-Y-表示任选被甲基取代的-C1-C2烷基C(O)R3-基团。
p)R3是自消除基团,其选自乙缩醛、羧基乙缩醛、羧基(甲基乙缩醛)、三甲基锁、对羟基苄基羰基或翻转酯自消除基团。
n)X'是O。
o)X'是S。
p)X'是N(R4)。
q)X'是N(H)S(O)2。
r)R4是H。
s)R4是C1-C4烷基。
t)R4是甲基。
在一个实施方案中,L是X’,且-Y-表示任选被取代的-C1烷基C(O)R3-。
因此,在另一个实施方案中,本发明提供表示为式(II)的式(I)的化合物:
其中
R1、R2和-X-如对式(I)所定义;
R3是自消除基团;
表示药用物质的残基;
-L-是-X’-;
X’是O、S、N(R4)或N(H)S(O)2;
R4是H或C1-C4烷基;
R5选自氢和C1-C4烷基;或者
其药学上可接受的盐。
在另一个实施方案中,L是X’,且-Y-表示任选被取代的-C2烷基C(O)R3-。
因此,在另一个实施方案中,本发明提供表示为式(III)的式(I)的化合物:
其中
R1、R2和-X-如对式(I)所定义;
R3是自消除基团;
表示药用物质的残基;
-L-是-X’-;
X’是O、S、N(R4)或N(H)S(O)2;
R4是H或C1-C4烷基;
R5和R6单独地选自氢和C1-C4烷基;或者
其药学上可接受的盐。
在另一个实施方案中,式(III)的化合物选自表1中所列出的那些化合物。
表1.式(III)的化合物:
1CASI=羧基乙缩醛自消除基团;2CMSI=羧基(甲基乙缩醛)自消除基团;3TML=三甲基锁自消除基团;4FSI-5=通过丧失5-碳内酯释放药用物质A的翻转酯自消除基团。
在另一个实施方案中,L是–OC(O)-,且-Y-表示任选被取代的-C1-C20烷基C(O)OCH2-、-C2-C20烯基C(O)OCH2-或-C2-C20炔基C(O)OCH2-基团;其中烷基、烯基或炔基基团上的碳原子的一个或多个可以被NH、S、O、C5-C8芳族或脂族环状基团或者C5-C8芳族或脂族杂环基团替代,条件是所述烷基、烯基或炔基基团不超过相当于直链C20烷基基团的长度。
因此,在另一个实施方案中,本发明提供表示为式(IV)的式(I)的化合物:
其中
R1、R2和-X-如对式(I)所定义;
表示药用物质的残基;
R5和R6单独地选自氢和C1-C4烷基;
R7是氢或C1-C4烷基;且
n是0至18;或者
其药学上可接受的盐。
在另一个实施方案中,式(IV)的化合物选自表2中所列出的那些化合物。
表2.式(IV)的化合物:
在一个实施方案中,所述的药用物质是睾酮或其衍生物或类似物。睾酮替代疗法(TRT)常用于具有性腺功能减退症(特征在于异常低血清睾酮水平的障碍)的患者以便将其血清睾酮水平恢复至正常范围,且由此缓解性腺功能减退症的许多症状,例如情绪紊乱、性功能障碍等。
因此,在一个实施方案中,本发明提供表示为式(V)的式(I)的化合物:
其中R1、R2和-X-如对式(I)所定义;
R5和R6单独地选自氢和C1-C4烷基;且
R3是自消除基团;或者
其药学上可接受的盐。
在另一个实施方案中,式(V)的化合物选自表3中所列出的那些化合物。
表3.式(V)的化合物:
/>
1ASI=乙缩醛自消除基团;2TML=三甲基锁自消除基团;3PHB=对羟基苄基羰基自消除基团;4FSI-4=通过丧失4-碳内酯释放药用物质A的翻转酯自消除基团;5FSI-5=通过丧失5-碳内酯释放药用物质A的翻转酯自消除基团;6CMSI=羧基(甲基乙缩醛)自消除基团。
在另一个实施方案中,本发明提供治疗或预防疾病或障碍的方法,在该疾病或障碍中增加的睾酮水平是有益的,该方法包括对有此需要的受试者施用治疗有效量的根据式(V)的化合物。
在还一个实施方案中,本发明提供根据式(V)的化合物在制备用于治疗或预防疾病或障碍的药剂中的用途,在该疾病或障碍中增加的睾酮水平是有益的。
在另一个实施方案中,本发明提供式(V)的化合物,其用于治疗或预防疾病或障碍,在该疾病或障碍中增加的睾酮水平是有益的。
增加的睾酮水平可能是有益的疾病和障碍包括,但不限于性腺功能减退症、因骨髓衰竭导致的贫血、因肾衰竭导致的贫血、慢性呼吸衰竭、慢性心力衰竭、类固醇依赖性自身免疫疾病、艾滋病消耗、遗传性血管水肿或荨麻疹、末期乳腺癌或绝经。
在另一个实施方案中,本发明提供一种促进药用物质的淋巴转运和***释放的方法,该方法包括使式(VI)的前药残基或其药学上可接受的盐缀合至所述的药用化合物:
其中
R1和R2独立地表示H或C2-C28脂肪酸的残基;
-X-选自-O-、-NH-和-S-;
-Y-表示任选被取代的-C1-C2烷基C(O)R3-基团或-C2烯基C(O)R3-或-C2炔基C(O)R3-基团;
R3是自消除基团;且
表示连接基与药物活性剂缀合的点。
在一个实施方案中,选择如上文所定义的化合物的包含“Y”和“R3”的连接基,以有利于药用物质稳定地转运至肠淋巴。在另一个实施方案中,选择Y和R3,以有利于药用物质在淋巴、淋巴细胞、淋巴组织、具有高脂肪酶活性的组织例如脂肪组织、一些癌症、肝脏中或在体循环中释放。在另一个实施方案中,对Y和R3进行选择,以有利于药用物质转运至肠淋巴并且有利于药用物质在淋巴、淋巴细胞、淋巴组织、具有高脂肪酶活性的组织例如脂肪组织、一些癌症、肝脏中或在体循环中释放。
本发明的化合物可用于稳定地将药用物质转运至肠淋巴并且在淋巴、淋巴细胞、淋巴组织、具有高脂肪酶活性的组织例如脂肪组织、一些癌症、肝脏中或在体循环中释放药用物质。本发明的化合物特别可用于转运和释放得益于避免首过代谢的药用物质,例如,表现出大于50%首过代谢的化合物。在一个实施方案中,预期所述药用物质表现出大于60%的首过代谢。在另一个实施方案中,所述的药用物质表现出大于70%的首过代谢。在另一个实施方案中,所述的药用物质表现出大于80%的首过代谢。在另一个实施方案中,所述的药用物质表现出大于90%的首过代谢。
可以得益于稳定地转运至肠淋巴并且在淋巴、淋巴细胞、淋巴组织、具有高脂肪酶活性的组织例如脂肪组织、一些癌症、肝脏中或在体循环中释放的药用物质包括,但不限于睾酮、麦考酚酸、***类(***)、***、四氢***酚、***二酚、美托洛尔、雷洛昔芬、阿法沙龙、他汀类药物例如阿托伐他汀、喷他佐辛、***、左旋多巴(L-DOPA)、丁丙诺啡、咪达***、利多卡因、氯丙嗪、阿米替林、去甲替林、喷他佐辛、硝酸异山梨酯、三***酯、氧烯洛尔、拉贝洛尔、维拉帕米、沙丁胺醇、环硫雄醇、美法仑、洛伐他汀和药物活性肽类。
本发明的化合物还可用于所述药用物质在淋巴***内的靶向释放,例如在淋巴、淋巴细胞和淋巴组织以及具有高脂肪酶活性的组织例如脂肪组织、一些癌症或肝中。
可以得益于在淋巴***或脂肪组织内靶向释放的药用物质包括,但不限于非甾类抗炎药(NSAIDS,例如阿司匹林、布洛芬、萘普生)、COX-2抑制剂(例如塞来昔布)、皮质类固醇抗炎药(例如***龙、***)、抗疟药(例如羟氯喹)、环磷酰胺、PPAR激动剂(例如贝特类)、亚硝基脲类、铂、甲氨蝶呤、硫唑嘌呤、巯嘌呤、氟尿嘧啶、放线菌素D、蒽环类、丝裂霉素C、博来霉素、光辉霉素、作用于抑免蛋白的药物(例如环孢素、他克莫司、西罗莫司)、柳氮磺吡啶、来氟米特、麦考酚酸酯、阿片样物质、芬戈莫德、多球壳菌素、苯丁酸氮芥、多柔比星、奈拉滨、可的松、***、***、普拉曲沙、长春碱、硼替佐米、噻替派、奈拉滨、盐酸柔红霉素、氯法拉滨、阿糖胞苷、达沙替尼、甲磺酸伊马替尼、盐酸普纳替尼、硫酸长春新碱、盐酸苯达莫司汀、磷酸氟达拉滨、波舒替尼、尼洛替尼、美琥他辛(omacetaxine,mepesuccinate)、阿那曲唑、卡培他滨、来曲唑、紫杉醇、吉西他滨、氟维司群、他莫昔芬、拉帕替尼、托瑞米芬、伊沙匹隆、艾立布林、阿苯达唑、伊维菌素、乙胺嗪、多西环素、氯生太尔、马拉韦罗、恩夫韦肽、脱氧胸腺嘧啶核苷、齐多夫定、司他夫定、去羟肌苷、扎西他滨、阿巴卡韦、拉米夫定、恩曲他滨、替诺福韦、奈韦拉平、地拉韦啶、依非韦伦、利匹韦林、拉替拉韦、艾维雷韦、洛匹那韦、茚地那韦、奈非那韦、氨普那韦、利托那韦、阿昔洛韦和免疫抑制剂例如麦考酚酸、环孢菌素、他克莫司和西罗莫司。
作为一般性的策略,本发明的化合物可以通过如下路径之一合成:
方案1.通式(II)的化合物的合成
可以使可轻易得自相应丙二酸的二酰氯i与甘油二酯ii在吡啶的存在下反应,得到酸-甘油三酯(酸-TG)iii(参见方案1)。
方案2.通式(III)的化合物的合成
在酸酐iv可得到的情况中,可以通过在吡啶的存在下用甘油二酯ii开环生成酸-TG iii(方案2)。当酸酐iv的R5和R6相同时,该方法实施最佳,但当R5和R6彼此不同时,该方法将得到酸-TG iii的区域异构体混合物。因此,其它方法,例如方案3中所概括的方法应当用于这种情况中。
方案3.式(III)的化合物的合成,其中R5=Me,R6=H。
为了在R5=Me且R6=H的具体实例中得到单一区域异构体形式的酸-TG iii,已知的羧酸v(Lienard,B.M.R.等人,Org.Biomol.Chem.2008,6,(13),2282-2292)可以用作起点(参见方案3)。在标准条件下酸v与1,3-DG ii偶联产生TBDPS保护的甘油三酯vi,可以将其用TBAF和AcOH处理,得到醇vii。然后可以使用两步氧化方法(PCC,然后KMnO4)经由中间体醛viii将醇vii转化成期望的酸-TG iii。
方案4.通式(III)化合物的合成,其中R3是乙缩醛自消除(ASI)基团,
且X’=O。
为了合成在药用物质与烷基间隔基之间包含乙缩醛自消除(ASI)基团的化合物,必须使带有醇的母体分子官能化并且活化,然后与酸-甘油三酯iii缀合,如上述方案4中所概括的。在乙酐与乙酸的混合物中用DMSO处理醇,导致形成(甲硫基)甲基(MTM)醚ix。采用磺酰氯活化MTM醚ix形成推定的亚砜类物质,可以使该亚砜类物质与酸-甘油三酯iii的羧酸酯反应,得到目标化合物x。
方案5.式(III)化合物的合成,其中R3是羧基乙缩醛(CASI)或羧基(甲基乙缩醛)(CMSI)自消除基团,且X’是O或N(R4)。
在药用物质包含醇、酚或胺(伯或仲)官能团的情况中,可以采用修饰形式的乙缩醛自消除基团,其中包括另外的羧基基团。母体药物与氯甲酸氯烷基酯反应,得到碳酸氯烷基酯或氨基甲酸氯烷基酯xi(参见方案5)。然后通过在回流的甲苯中用衍生自酸-TG iii的羧酸酯处理来置换卤化物离去基得到目标化合物xii。
方案6.式(III)化合物的合成,其中R3是三甲基-锁(TML)自消除基团,且X’=O、NR4或S(O)2NH。
为了合成在药用物质与烷基间隔基之间包含三甲基锁(TML)自消除基团(Levine,M.N.;Raines,R.T.Chem.Sci.2012,3,2412-2420)以有利于母体分子的***释放的前药,必须用TML部分使酸-甘油三酯iii官能化,然后与药用物质缀合,如上述方案6中所概括的。在标准条件下酸-TG iii与TML苯酚xiii偶联,得到甘油三酯xiv,可以在酸性条件下(10-樟脑磺酸)使其脱保护,得到醇xv。依次地首先将醇xv氧化成醛xvi,然后氧化成酸xvii,接着与包含醇、胺或磺酰胺的药用物质在标准条件下偶联,可以得到目标化合物xviii。
方案7.式(III)化合物的合成,其中R3是对羟基苄基羰基(PHB)自消除基团,且X’=O、S或NR4。
为了合成包含对羟基苄基(PHB)羰基自消除基团的化合物,首先将对羟基苄醇(xix)的伯羟基基团保护为甲硅烷基醚,并且使游离酚羟基基团与酸-TG iii偶联,得到PHB甘油三酯xxi(参见方案7)。在除去硅保护基后,可以通过用氯甲酸对硝基苯基(PNP)酯处理来活化伯醇xxii,得到碳酸PNP酯xxiii。然后通过与药用物质(A–X’H)在碱性条件下反应实现PNP基团的置换,得到期望的化合物xxiv。
方案8.式(III)化合物的合成,其中R3是翻转酯自消除(FSI)基团,且X’=O、S或NR4。
设计翻转酯自消除(FSI)基团以通过环化机制,导致4-碳(FSI-4)或5-碳(FSI-5)内酯丧失,释放游离药用物质。可以通过使药用物质(A–X’H)与4-溴丁酸(m=1)或5-溴戊酸(m=2)(xxv)偶联来合成FSI前药,得到溴化物xxvi(参见方案8)。采用衍生自酸-TG iii的羧酸酯置换溴化物xxvi生成期望的目标化合物xxvii中的酯键。
方案9.式(V)化合物的合成
在药用物质包含羧酸的情况中,必须将酸-TG iii转化成相应的酰氯,然后用三烷(R7=H)或三聚乙醛(R7=Me)在ZrCl4或ZnCl2的存在下处理,得到氯烷基酯xxviii(参见方案9)。然后可以通过与衍生自母体药物的羧酸酯反应来实现卤化物的置换,得到目标化合物xxix。
如果本发明的化合物需要纯化,则可以使用多种技术例如重结晶和色谱技术,包括高效液相色谱法(HPLC)和正向或反相硅胶色谱法。所述化合物可以用核磁共振(NMR)质谱法和/或其它适合的方法进行表征。
将被理解,本发明的化合物可以以一种或多种立体异构体形式存在(例如非对映异构体)。本发明在其范围内包括所有这些分离(例如对映体分离)或组合(包括外消旋混合物和非对映异构体混合物)的立体异构体形式。
因此本发明还涉及基本上纯的立体异构体形式的化合物,例如大于约90%de,例如约95%至97%de或大于99%de,以及混合物,包括其外消旋混合物。这类非对映异构体可以通过不对称合成,例如采用手性中间体来制备,或可以通过常规方法拆分混合物,例如色谱法或应用拆分试剂。
如果所述化合物包含一个或多个可被质子化或脱质子化的官能团(例如在生理pH下),则该化合物可以作为药学上可接受的盐制备和/或分离。将被理解,所述化合物在指定pH下可以为两性离子形式。本文所用的表述“药学上可接受的盐”是指所指定的化合物的盐,其中该盐适合于作为药物施用。这类盐可以通过分别使酸或碱与胺或羧酸基团反应形成。
药学上可接受的酸加成盐可以由无机酸和有机酸制备。无机酸的实例包括盐酸、氢溴酸、硫酸、硝酸、磷酸等。有机酸的实例包括乙酸、丙酸、乙醇酸、丙酮酸、草酸、苹果酸、丙二酸、琥珀酸、马来酸、富马酸、酒石酸、柠檬酸、苯甲酸、肉桂酸、扁桃酸、甲磺酸、乙磺酸、对甲苯磺酸、水杨酸等。
药学上可接受的碱加成盐可以由无机碱和有机碱制备。衍生自无机碱的相应平衡离子包括钠、钾、锂、铵、钙和镁盐。有机碱包括伯胺、仲胺和叔胺类、取代的胺类包括天然存在的取代的胺类和环胺类,包括异丙基胺、三甲胺、二乙胺、三乙胺、三丙胺、乙醇胺、2-二甲氨基乙醇、氨丁三醇、赖氨酸、精氨酸、组氨酸、咖啡因、普鲁卡因、海巴明(hydrabamine)、胆碱、甜菜碱、乙二胺、葡糖胺、N-烷基葡糖胺、可可碱、嘌呤、哌嗪、哌啶和N-乙基哌啶。
酸/碱加成盐比相应的游离酸/碱形式倾向于更溶于水性溶剂。
本发明的化合物可以为晶型或为溶剂合物(例如水合物),并且预期两者均在本发明的范围内。术语“溶剂合物”是溶质和溶剂形成的可变化学计算量的复合物。这类溶剂不应当干扰溶质的生物活性。作为实例,溶剂可以为水、乙醇或乙酸。溶剂化方法是本领域中公知的。
本发明化合物的施用途经预期包括经口和经肠施用。因此,该活性化合物可以用惰性稀释剂或可同化的可食用载体配制,或可以将其包封在硬壳胶囊或软壳胶囊内,或可以将其压制成片剂,或可以将其直接掺入膳食食物。为了口服治疗施用,可以将活性化合物与赋形剂掺合并且以可摄入片剂、***或舌下片、锭剂、胶囊、酏剂、混悬液、糖浆剂、糯米纸囊剂等形式使用。活性化合物在这类治疗上有用的组合物中的量是将得到适合剂量的量。
所述片剂、锭剂、丸剂、胶囊等还可以包含如下文所列出的成分:粘合剂,例如树胶、***胶、玉米淀粉或明胶;赋形剂,例如磷酸二钙;崩解剂,例如玉米淀粉、马铃薯淀粉、藻酸等;润滑剂,例如硬脂酸镁;以及甜味剂,例如蔗糖、乳糖或糖精,或矫味剂,例如薄荷、冬青油或樱桃香精。当剂型是胶囊时,除上述类型的物质外,它还可以包含液体载体。各种其它材料可以作为包衣衣料提供,否则可以改变剂型的物理形式。例如,可以用虫胶、糖或它们两者给片剂、丸剂或胶囊包衣。糖浆剂或酏剂可以包含活性化合物、作为甜味剂的蔗糖、作为防腐剂的对羟基苯甲酸甲酯和对羟基苯甲酸丙酯、染料和矫味剂例如樱桃或橙子香精。当然,用于制备任意单位剂型的任意材料应当是药学纯的且在使用量上基本上是无毒的。此外,可以将本发明的化合物掺入缓释制品和制剂,包括能够将活性肽特异性地递送至肠的特定区域的那些。
还可以通过胃管或食道管经肠施用液体制剂。
在一个实施方案中,将本发明的化合物与食物一起经口施用以促进转运至肠淋巴。
在另一个实施方案中,与食物共同施用或不与食物共同施用,将本发明的化合物与基于脂质的制剂一起经口施用以促进转运至肠淋巴。
用于经口递送的基于脂质的制剂是本领域中已知的且可以包括,例如基本上非水的介质,其典型地包含一种或多种脂质成分。脂质介质和得到的脂质制剂可以有用地如下所述根据其共有公同特征,按照脂质制剂分类***(LFCS)进行分类(Pouton,C.W.,Eur.J.Pharm.Sci.11(增刊2),S93-S98,2000;Pouton,C.W.,Eur.J.Pharm.Sci.29 278-287,2006)。
因此,脂质介质和得到的脂质制剂可以包含油/脂质和/或表面活性剂,任选地含有助溶剂。I型制剂包括需要消化的油或脂质,例如单甘油酯、二甘油酯和三甘油酯类及其组合。II型制剂是不溶于水的自乳化递药***(SEDDS),其包含用于I型制剂中的脂质和油以及另外的不溶于水的表面活性剂。III型制剂为SEDDS或自微乳化递药***(SMEDDS),其包含用于I型制剂中的脂质和油以及另外的水溶性表面活性剂和/或助溶剂(IIIa型)或更大比例的水溶性成分(IIIb型)。IV型制剂主要包含亲水性表面活性剂和助溶剂(例如PEG、丙二醇和二甘醇一***)并且可用于难溶于水但非亲脂性的药物。本申请中包括任意这类脂质制剂(I-IV型)。
在一些实施方案中,脂质介质包含一种或多种油或脂质,不含额外的表面活性剂、辅助表面活性剂或辅助乳化剂或助溶剂,也就是说,它主要由一种或多种油或脂质组成。在另外一些实施方案中,脂质介质包含一种或多种油或脂质与一种或多种不溶于水的表面活性剂,任选地连同一种或多种助溶剂。在另外一些实施方案中,脂质介质包含一种或多种油或脂质与一种或多种水溶性表面活性剂,任选地连同一种或多种助溶剂。在一些实施方案中,脂质介质包含油/脂质、表面活性剂和助溶剂的混合物。在一些实施方案中,脂质介质基本上由一种或多种表面活性剂/辅助表面活性剂/辅助乳化剂和/或溶剂/助溶剂组成。
可以用于本发明中的油或脂质的实例包括杏仁油、巴巴苏油、黑醋栗种子油、琉璃苣油、介花油、蓖麻油、椰子油、鳕鱼肝油、玉米油、棉籽油、月见草油、鱼油、葡萄籽油、芥菜籽油、橄榄油、棕榈仁油、棕榈油、花生油、菜籽油、红花油、芝麻油、鲨鱼肝油、大豆油、向日葵油、胡桃油、小麦胚芽油、鳄梨油、糠油、氢化蓖麻油、氢化椰子油、氢化棉籽油、氢化棕榈油、氢化大豆油、部分氢化大豆油、氢化植物油、辛酸/癸酸甘油三酯、分级分离的甘油三酯、三癸酸甘油酯、三己酸甘油酯、三辛酸甘油酯、三辛酸/癸酸甘油酯、三辛酸/癸酸甘油酯、三辛酸/癸酸/月桂酸甘油酯、三辛酸/癸酸/亚油酸甘油酯、三辛酸/癸酸/硬脂酸甘油酯、三月桂酸甘油酯、单月桂酸甘油酯、山嵛酸甘油酯、单亚油酸甘油酯、三亚油酸甘油酯、三油酸甘油酯、三十一酸甘油酯、甘油基三硬脂酸酯亚油酸甘油酯、饱和聚乙二醇化甘油酯、主要包含C8-C12脂肪酸链的合成中链甘油三酯、主要包含C8-C12脂肪酸链的中链甘油三酯、主要包含>C12脂肪酸链的长链甘油三酯、修饰的甘油三酯、分级分离的甘油三酯以及它们的混合物。
可以用于本发明中的单酸甘油酯和甘油二酯的实例包括具有8-40个碳原子的脂肪酸链的一酯和二酯类,包括水解的椰子油(例如MCM)、水解的玉米油(例如MaisineTM35-1)。在一些实施方案中,单酸甘油酯和甘油二酯是具有8-18个碳链长度的脂肪酸链的甘油的单饱和脂肪酸酯类或二饱和脂肪酸酯类(例如单硬脂酸甘油酯、二硬脂酸甘油酯、单辛酸甘油酯、二辛酸甘油酯、单癸酸甘油酯和二癸酸甘油酯)。
用于脂质制剂中的适合表面活性剂包括C8-C22脂肪酸的丙二醇一酯和二酯,例如,但不限于丙二醇单辛酸酯、丙二醇二辛酸酯、丙二醇单月桂酸酯,其以商品名例如90、/>PG、/>FCC销售;糖脂肪酸酯类,例如,但不限于棕榈酸蔗糖酯、月桂酸蔗糖酯、硬脂酸蔗糖酯;脱水山梨糖醇脂肪酸酯类,例如,但不限于月桂山梨坦、棕榈山梨坦、油酸山梨坦;聚氧乙烯水山梨糖醇脂肪酸酯类,例如,但不限于聚山梨醇酯20、聚山梨醇酯40、聚山梨醇酯60和聚山梨醇酯80、聚山梨醇酯85;聚氧乙烯一脂肪酸酯类和二脂肪酸酯类,包括,但不限于聚氧乙烯40硬脂酸酯和聚氧乙烯40油酸酯;C8-C22脂肪酸的聚氧乙烯一酯类和二酯类的混合物和C8-C22脂肪酸的甘油一酯类、二酯类和三酯类,其销售商品名为例如/>44/14、/>50/13、聚氧乙烯蓖麻油化合物,例如,但不限于聚氧乙烯35蓖麻油、聚氧乙烯40氢化蓖麻油和聚氧乙烯60氢化蓖麻油,其作为商品名例如/>EL、RH40、/>RH60销售;聚氧乙烯烷基醚,包括,但不限于聚氧乙烯20十六烷基十八烷基醚和聚氧乙烯10油醚;DL-.α.-生育酚聚乙二醇琥珀酸酯,其可以作为商品名销售;甘油一酯、二酯和三酯;C8-C22脂肪酸的甘油一酯、二酯和三酯;蔗糖一酯、二酯和三酯;磺基琥珀酸二辛酸钠;聚氧乙烯-聚氧丙烯共聚物,例如,但不限于泊洛沙姆124、泊洛沙姆188、泊洛沙姆407;C8-C22脂肪醇的聚氧乙烯醚类,包括,但不限于聚氧乙烯月桂醇、聚氧乙烯鲸蜡醇、聚氧乙烯十八烷醇、聚氧乙烯油醇,其销售用的商品名为例如/>35、/>58、/>78/>98;或者它们的任意两种或更多种的混合物。
辅助乳化剂或辅助表面活性剂可以用于制剂中。适合的辅助乳化剂或辅助表面活性剂可以是磷酸甘油酯;磷脂,例如卵磷脂或游离脂肪酸,其在室温下为液体,例如异硬脂酸、油酸、亚油酸、亚麻酸、棕榈酸、硬脂酸、月桂酸、癸酸、辛酸和己酸。
适合的溶剂/助溶剂包括乙醇、丙二醇、聚乙二醇、二甘醇一***和甘油。
聚合物也可以用于制剂中以抑制药物沉淀或改变药物释放速率。已经证实一系列聚合物可以影响这些特性且它们是本领域技术人员众所周知的。适合的聚合物包括羟丙基甲基纤维素、羟丙基甲基纤维素乙酰基琥珀酸酯、其它纤维素衍生的聚合物例如甲基纤维素;聚(甲基)丙烯酸酯类,例如Eudragit系列聚合物,包括Eudragit E100、聚乙烯吡咯烷酮或例如Warren等人Mol.Pharmaceutics 2013,10,2823-2848中所述的其它聚合物。
可以对制剂进行特别地选择,以提供活性成分在胃肠(GI)道中的持续释放,以便控制吸收速率。许多不同的方法可以用于实现这些目标,包括应用在GI道中缓慢地分散/浸蚀的高熔点脂质或形成缓慢地浸蚀的基质。这些制剂可以采用大整体型剂型的形式或可以作为微粒或纳米粒基质提供,例如如Mishra,Handbook of Encapsulation andControlled Release,CRC Press,Boca Raton,(2016)ISBN 978-1-4822-3234-9,Wilson和Crowley Controlled Release in Oral Drug Delivery,Springer,NY,ISBN 978-1-4614-1004-1(2011)或Wise,Handbook of Pharmaceutical Controlled Release Technology,Marcel Dekker,NY,ISBN 0-82467-0369-3(2000)中所述。
制剂还可以包含本领域技术人员通常已知基于脂质的制剂中包括的物质,包括抗氧化剂,例如丁羟茴醚(BHA)或丁羟甲苯(BHT);以及固化剂,例如微孔二氧化硅,例如偏硅酸铝镁(Neusilin)。
在另一个实施方案中,所述的化合物可以与酶抑制剂一起经口共同施用以增加前药在胃肠道或肠细胞中的稳定性。在一些实施方案中,想到所述酶抑制剂抑制胰脂肪酶,其实例包括,但不限于Alli和奥利司他。在其它实施方案中,想到所述酶抑制剂抑制细胞脂肪酶,例如一酰基甘油脂肪酶,其实例包括,但不限于JZL184(4-硝基苯基-4-[双(1,3-苯并间二氧杂环戊烯-5-基)(羟基)甲基]哌啶-1-甲酸酯)。
尽管如上文所述的化合物或其药学上可接受的盐可以以单独的活性成分施用于受试者,但是其它活性成分与所述化合物一起施用属于本发明的范围。在一个或多个实施方案中,想到本发明的化合物的两种或更多种的组合施用于受试者。
本发明还提供药物组合物,其包含治疗有效量的如上文所定义的化合物或其药学上可接受的盐与至少一种药学上可接受的载体或稀释剂。
术语“组合物”预期包括活性成分与作为载体的包囊材料的制剂,得到胶囊,其中活性成分(与其它载体一起或不与其它载体一起)被载体包围。
正如本领域技术人员易于理解的,药学上可接受的载体的性质取决于被治疗的病症和哺乳动物的性质。认为特定载体或递送***的选择易于由本领域技术人员确定。在制备包含活性化合物的任意制剂的过程中,应当小心以确保化合物的活性不在该过程中被破坏,且该化合物能够达到其作用部位而不受破坏。在一些情形中,有必要通过本领域公知的方式保护化合物,例如,微囊化。
本领域技术人员采用常规方法可以轻易地确定用于本发明化合物的适合制剂。在本领域中鉴定优选的pH范围和适合的赋形剂例如抗氧化剂是常规的。缓冲***常用于提供期望范围的pH值,并且包括羧酸缓冲液,例如乙酸盐、柠檬酸盐、乳酸盐和琥珀酸盐。各种抗氧化剂可以利用于这类制剂中,包括酚类化合物,例如BHT或维生素E、还原剂例如甲硫氨酸或亚硫酸盐和金属螯合剂例如EDTA。
药学上可接受的介质和/或稀释剂包括任意和所有的溶剂、分散介质、包衣、抗菌剂和抗真菌剂、等渗剂和吸收延迟剂等。这类介质和试剂对于药物活性物质的应用是本领域中众所周知的。除了任意常用介质或试剂与活性成分不相容,其在治疗组合物中的应用被考虑。还可以将补充活性成分掺入组合物。
还可以将所述化合物与一种或多种其它治疗剂以组合方式施用。该组合能够单独、依次或同时施用上文所述的化合物与其它活性成分。该组合物可以以药物组合物的形式提供。
如本申请中所用,术语“组合”是指组合物或部件套装产品,其中上文所定义的组合伴侣可以以依赖性或独立方式施用或通过使用与差别量的组合伴侣的不同固定组合来施用,即同时或在不同时间点施用。然后,例如,可以将组合伴侣同时或按时间交错施用,对于部件套装产品的不同组成部分,其可以在不同的时间点和相同或不同时间间隔施用。组合中施用的组合伴侣的总量的比例可变,例如,以便符合被治疗的患者亚群的需求或单一患者的需求,该不同需求可以归因于该患者的年龄、性别、体重等。
尤其有利的是配制单位剂型形式的组合物,其易于施用且剂量均匀。如本申请中所用的单位剂型是指适合于作为被治疗的哺乳动物受试者的单元剂量的物理分散单元;每个单元包含预定量的活性物质,经计算其与所需的药学上可接受的介质结合产生期望的治疗作用。用于本发明新的单位剂型的规格根据如下因素指定并且直接取决于如下因素:(a)活性物质的独特特征和所实现的特定治疗作用;以及(b)混合用于治疗具有病况的活受试者的疾病的活性物质领域中内在的限制,如本申请中详细描公开的,所述受试者中身体健康受损。
如上所述,可以混合主要活性成分,以方便和有效地以治疗有效量与适合的药学上可接受的介质一起在单位剂型中施用。例如,单位剂型可以包含量为0.25μg-约2000mg的主要活性化合物。按照比例表示,活性化合物的存在量约为0.25μg-约2000mg/mL载体。在包含补充活性成分的组合物的情况中,可以参照所述成分的常用剂量和施用方式确定剂量。
如本申请中所用,术语“有效量”是指当根据期望的施药方案施用时提供期望的治疗活性的化合物的量。施药可以1次进行或以数分钟或数小时间隔进行,或在这些期限的任意一个内连续进行。适合的剂量可以在约0.1纳克/千克体重至1克/千克体重/剂量的范围。典型剂量为1微克至1克/千克体重/剂量,例如1毫克至1克/千克体重/剂量。在一个实施方案中,该剂量可以为1毫克至500毫克/千克体重/剂量。在另一个实施方案中,该剂量可以为1毫克至250毫克/千克体重/剂量。在另一个实施方案中,该剂量可以为1毫克至100毫克/千克体重/剂量,例如至多50毫克/千克体重/剂量。
如本申请中所用,术语“治疗”涵盖动物,优选哺乳动物,更优选人的病症或疾病的任意治疗,且包括治疗其中睾酮水平增加为有益的任意疾病或障碍。如本申请中所用,术语“预防”涵盖动物,优选哺乳动物,更优选人的病症或疾病的预防,且包括预防其中睾酮水平增加为有益的任意疾病或障碍。
除非另有要求,否则在本说明书和权利要求书的自始至终中的措词“包含”和变化形式例如“含有”或“包括”将被理解为暗示包含所述整体或步骤或整体或步骤组,但不排除任意其它整体或整体组。
本说明书中涉及任意现有出版物(或来源于它的信息)或已知的任意材料,不被且不应被视为认可或承认或任意形式建议现有出版物(或来源于它的信息)或已知的材料构成本说明书所涉及的领域中的公知常识的组成部分。
现在参照下列非限制性实施例描述本发明。下列实施例是通式(I)的代表,并且提供了用于制备本发明示例性化合物的详细方法。
实施例1.由酸酐合成酸-甘油三酯
4-((1,3-双(棕榈酰氧基)丙-2-基)氧基)-4-氧代丁酸(iii)
将琥珀酸酐(iv)(25.4mg,0.254mmol)和DMAP(15.5mg,0.127mmol)加到甘油二酯ii(72.2mg,0.127mmol)在吡啶(0.5mL)、CH2Cl2(0.5mL)和THF(0.5mL)中的溶液中,将该混合物在室温搅拌17小时。此时TLC分析显示存在未反应的甘油二酯,因此再加入琥珀酸酐(25.4mg,0.254mmol)和DMAP(15.5mg,0.127mmol),将该反应体系在40℃再加热22小时。将该混合物冷却至室温,用乙酸乙酯(20mL)稀释,用1M HCl(10mL)和盐水(2×30mL)洗涤,干燥(MgSO4),减压浓缩,得到粗产物。通过硅胶色谱法纯化(15%-20%-25%乙酸乙酯/己烷),得到酸-TG iii(77.0mg,91%),为无色固体。
1H NMR(400MHz,CDCl3)δ5.27(m,1H),4.30(dd,J=12.0,4.3Hz,2H),4.15(dd,J=12.0,5.8Hz,2H),2.72–2.61(m,4H),2.31(t,J=7.6Hz,4H),1.66–1.54(m,4H),1.35–1.19(m,48H),0.87(t,J=6.9Hz,6H)。
4-((1,3-双(棕榈酰氧基)丙-2-基)氧基)-3/2-甲基-4-氧代丁酸(iii)
将4-(二甲氨基)吡啶(64.6mg,0.527mmol)加到甘油二酯ii(200mg,0.351mmol)和甲基琥珀酸酐(iv)(101mg,0.882mmol)在吡啶/THF/CH2Cl2(各2.5mL)中的溶液中,将该混合物在室温搅拌22小时。用乙酸乙酯(40mL)稀释该反应体系,用1M HCl(30mL)和盐水(3×30mL)洗涤,干燥(MgSO4),减压浓缩,得到粗制酸-TG iii(~1:1区域异构体混合物,240mg,定量),为无色固体,未纯化将其用于下一个反应。
1H NMR(400MHz,CDCl3)δ5.31–5.24(m,1H),4.34–4.27(m,2H),4.21–4.10(m,2H),3.00–2.90(m,1H),2.82–2.72(m,1H),2.52–2.43(m,1H),2.37–2.28(m,4H),1.67–1.55(m,4H),1.46(d,J=7.0Hz,3H),1.36–1.17(m,48H),0.88(t,J=6.8Hz,6H)。注意:整合和多重性反映出存在区域异构体混合物。
实施例2.酸-甘油三酯的合成,其中R5是甲基
a)二棕榈酸2-((4-((叔丁基二苯基甲硅烷基)氧基)-2-甲基丁酰基)氧基)丙-1,3-二基酯(vi)
将4-(二甲氨基)吡啶(DMAP,59.9mg,0.491mmol)和EDC·HCl(235mg,1.23mmol)加到酸v(175mg,0.491mmol)和1,3-DG ii(293mg,0.515mmol)在CH2Cl2(8mL)中的溶液中,将该混合物在室温搅拌16小时。用CH2Cl2(20mL)稀释该反应体系,加入硅胶,减压浓缩该混合物。通过硅胶色谱法纯化(3%-10%乙酸乙酯/己烷),得到甘油三酯vi(406mg,91%),为无色油状物。
1H NMR(400MHz,CDCl3)δ7.67–7.63(m,4H),7.45–7.34(m,6H),5.25(m,1H),4.30–4.22(m,2H),4.15–4.08(m,2H),3.69(t,J=6.3Hz,2H),2.75(m,1H),2.27(t,J=7.2Hz,2H),2.25(t,J=7.2Hz,2H),1.99(m,1H),1.64–1.55(m,5H),1.32–1.20(m,48H),1.14(d,J=7.2Hz,3H),1.04(s,9H),0.88(t,J=7.0Hz,6H)。
b)二棕榈酸2-((4-羟基-2-甲基丁酰基)氧基)丙-1,3-二基酯(vii)
在0℃将氟化四丁基铵(TBAF,1.0M的THF溶液,810μL,0.810μmol)和乙酸(46.1mL,0.810mmol)加到TBDPS醚vi(406mg,0.447μmol)在THF(20mL)中的溶液中,将该混合物在室温搅拌3小时。用水(30mL)稀释该反应体系,用乙酸乙酯(3×20mL)萃取,用盐水(30mL)洗涤有机萃取物,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(0%-25%乙酸乙酯/己烷),得到醇vii(137mg,46%),为无色固体。
1H NMR(400MHz,CDCl3)δ5.27(m,1H),4.39(dd,J=12.0,4.1Hz,1H),4.32(dd,J=11.9,4.3Hz,1H),4.16(dd,J=12.0,6.0Hz,1H),4.12(dd,J=12.0,5.6Hz,1H),3.74–3.63(m,2H),2.66(m,1H),2.316(t,J=7.6Hz,2H),2.309(t,J=7.4Hz,2H),1.91(m,1H),1.70(m,1H),1.63–1.58(m,4H),1.34–1.25(m,48H),1.19(d,J=7.1Hz,3H),0.88(t,J=6.9Hz,6H)。
c)二棕榈酸2-((2-甲基-4-氧代丁酰基)氧基)丙-1,3-二基酯(viii)
在0℃将氯铬酸吡啶(PCC,89.1mg,0.410mmol)加到醇vii(137mg,0.205mmol)和C盐(Celite)(90mg)在CH2Cl2(12mL)中的混悬液中,将该混合物在室温搅拌2.5小时。通过短硅胶垫过滤该反应体系,用50%乙酸乙酯/己烷洗脱,减压浓缩滤液,得到粗制醛viii(134mg,定量),为黄色油状物,其未经纯化而被使用。
1H NMR(400MHz,CDCl3)δ9.75(s,1H),5.27(m,1H),4.30(dd,J=12.0,4.2Hz,2H),4.16–4.09(m,2H),2.99(m,1H),2.89(ddd,J=18.1,7.8,0.8Hz,1H),2.55(ddd,J=18.0,5.5,0.9Hz,1H),2.32(t,J=7.4Hz,2H),2.30(t,J=7.4Hz,2H),1.64–1.58(m,4H),1.33–1.25(m,48H),1.22(d,J=7.1Hz,3H),0.88(t,J=7.0Hz,6H)。
d)4-((1,3-双(棕榈酰氧基)丙-2-基)氧基)-3-甲基-4-氧代丁酸(iii)
将高锰酸钾(65.4mg,0.410μmol)加到在丙酮(7.5mL)和水(2.5mL)中的醛viii(134mg,0.205μmol)中,将该混合物在室温搅拌19小时。用水(25mL)稀释该反应体系,用1MHCl酸化至pH 2,用CH2Cl2(3×20mL)萃取水层。用盐水(30mL)洗涤合并的有机萃取物,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(10%-25%乙酸乙酯/己烷),得到酸iii(79.6mg,58%),为无色固体。
1H NMR(400MHz,CDCl3)δ5.27(m,1H),4.32–4.27(m,2H),4.18–4.12(m,2H),2.92(m,1H),2.78(dd,J=16.9,8.0Hz,1H),2.46(dd,J=16.9,6.0Hz,1H),2.304(t,J=7.6Hz,2H),2.297(t,J=7.6Hz,2H),1.62–1.56(m,4H),1.31–1.19(m,51H),0.88(t,J=6.8Hz,6H)。
实施例3.通式(III)的化合物的合成,其中
R3是乙缩醛自消除(ASI)基团
((((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊并[a]菲-17-基)氧基)甲基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(12)
在0℃将磺酰氯(13.3μL,0.164mmol)在CH2Cl2(1mL)中的溶液加到MTM醚ix(46.9mg,0.135mmol)在CH2Cl2(2mL)中的溶液中,将该混合物在0℃搅拌30分钟,然后在室温再搅拌1小时。在N2气流中浓缩该反应体系,从甲苯(2×5mL)中共蒸发,减压浓缩。然后将粗制残余物再溶于甲苯(1.5mL),加到预先搅拌1小时的酸iii(50.0mg,0.0747mmol)和DBU(16.8μL,0.112mmol)在甲苯(1.5mL)中的溶液中,将该混合物在室温搅拌2小时。用CH2Cl2(20mL)稀释该反应体系,用饱和NaHCO3水溶液(20mL)和盐水(20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(含有0.5% Et3N的10%-25%乙酸乙酯/己烷),得到化合物12(8.4mg,12%),为淡黄色油状物。
1H NMR(400MHz,CDCl3)δ5.73(s,1H),5.34–5.23(m,3H),4.30(dd,J=11.9,4.4Hz,2H),4.15(dd,J=11.9,5.8Hz,2H),3.54(dd,J=8.3,8.3Hz,1H),2.65(s,4H),2.48–2.24(m,8H),2.09–1.99(m,2H),1.92–1.80(m,2H),1.74–1.36(m,9H),1.35–1.21(m,49H),1.19(s,3H),1.17–0.91(m,5H),0.88(t,J=6.9Hz,6H),0.80(s,3H)。
ESI-HRMS:计算值C59H101O10[M+H+]969.7389;测定值969.7409.
4-((((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊并[a]菲-17-基)氧基)甲基)2/3-甲基琥珀酸1-(1,3-双(棕榈酰氧基)丙-2-基)酯(13/14)
在0℃将磺酰氯(21.4μL,0.264mmol)在CH2Cl2(1.5mL)中的溶液加到MTM醚ix(76.3mg,0.219mmol)在CH2Cl2(3mL)中的溶液中,将该混合物在0℃搅拌30分钟,然后在室温再搅拌45分钟。在N2气流中浓缩该反应体系,从甲苯(2×5mL)中共蒸发,减压浓缩。然后将粗制残余物再溶于甲苯(2.5mL),加到预先搅拌45分钟的酸iii(99.4mg,0.146mmol)和DBU(32.8μL,0.220mmol)在甲苯(2.5mL)中的溶液中,将该混合物在室温搅拌3小时。用乙酸乙酯(20mL)稀释该反应体系,用饱和NaHCO3水溶液(2×20mL)和盐水(2×20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(含有0.5% Et3N的5%-15%乙酸乙酯/己烷),得到化合物13和14(1:1区域异构体混合物,74.2mg,52%),为淡黄色油状物。
1H NMR(400MHz,CDCl3)δ5.73(s,1H),5.38–5.21(m,3H),4.32–4.25(m,2H),4.20–4.10(m,2H),3.58–3.50(m,1H),2.98–2.87(m,1H),2.81–2.71(m,1H),2.47–2.24(m,9H),2.08–1.98(m,2H),1.92–1.80(m,2H),1.75–1.51(m,8H),1.50–1.20(m,53H),1.19(s,3H),1.17–0.89(m,5H),0.88(t,J=7.0Hz,6H),0.80(s,1.5H),0.79(s,1.5H)。注意:除可能的非对映异构体外,整合和多重性还反映出存在1:1个区域异构体混合物。
4-((((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊并[a]菲-17-基)氧基)甲基)2-甲基琥珀酸1-(1,3-双(棕榈酰氧基)丙-2-基)酯(13)
如上所述由酸-TG iii的α-甲基区域异构体制备。
1H NMR(400MHz,CDCl3)δ5.72(s,1H),5.32–5.22(m,3H),4.29/4.27(各自dd,J=12.0,4.2Hz,2H),4.17/4.14(各自dd,J=11.9,6.0Hz,2H),3.529/3.524(各自t,J=8.3Hz,1H),2.93(m,1H),2.75(dd,J=16.8,7.9Hz,1H),2.49–2.23(m,9H),2.08–1.96(m,2H),1.91–1.79(m,2H),1.71(m,1H),1.67–1.51(m,8H),1.49–1.07(m,51H),1.22(d,J=7.2Hz,3H),1.18(s,3H),1.06–0.90(m,3H),0.87(t,J=6.8Hz,6H),0.79(s,3H)。注意:双信号(例如:4.29/4.27)反映出存在非对映异构体混合物。
ESI-HRMS:计算值C60H102O10Na[M+Na+]1005.7365;测定值1005.7370.
实施例4.通式(III)的化合物的合成,其中R3是羧基-乙缩醛
或羧基-甲基乙缩醛自消除(CASI或CMSI)基团
a)((1S,4S)-4-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)(甲基)氨基甲酸氯甲酯(xi)
在0℃将氯甲酸氯甲酯(25.9μL,0.292mmol)和吡啶(41.3μL,0.511mmol)加到在CH2Cl2(4mL)中的盐酸舍曲林(50.0mg,0.146mmol)中,将该混合物在0℃搅拌15分钟,然后在室温搅拌1小时。用CH2Cl2(20mL)稀释该反应体系,用饱和NaHCO3水溶液(20mL)和盐水(20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到氨基甲酸氯甲酯xi(58.2mg,定量),为淡黄色油状物,其未经纯化而被使用。
1H NMR(400MHz,CDCl3)δ7.34(d,J=8.3Hz,1H),7.31–7.25(m,1H),7.24–7.16(m,1H),7.11–7.06(m,1H),6.97(dd,J=7.0,2.0Hz,1H),6.84–6.79(m,1H),5.91–5.83(m,1H),5.51(dd,J=10.4,6.5Hz,0.6H),5.32(dd,J=14.5,6.1Hz,0.4H),4.20(dd,J=5.2,2.9Hz,1H),2.78(s,1.2H),2.72(s,1.8H),2.36–2.22(m,1H),2.07–1.99(m,1H),1.87–1.70(m,2H)。注意:部分整合反映出存在旋转异构体混合物。
b)(((((1S,4S)-4-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)(甲基)氨基甲酰基)氧基)甲基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(1)
将1,8-二氮杂双环[5.4.0]十一-7-烯(DBU)(7.8μL,52.2μmol)加到酸-TG iii(25.1mg,37.5μmol)、氨基甲酸氯甲酯xi(13.0mg,32.6μmol)和碘化四丁基铵(TBAI,3.6mg,9.8μmol)在甲苯(1.2mL)中的混悬液中,将该混合物回流加热1小时。将该反应体系冷却至室温,用乙酸乙酯(20mL)稀释,用水和盐水(各20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。进行硅胶色谱法(15%乙酸乙酯/己烷),得到化合物1(29.0mg,86%),为无色油状物。
1H NMR(400MHz,CDCl3)δ7.33(d,J=8.3Hz,1H),7.30–7.24(m,1H),7.22–7.17(m,2H),7.09(d,J=2.0Hz,1H),6.96(d,J=7.3Hz,1H),6.84–6.78(m,1H),5.89–5.83(m,2H),5.49(dd,J=10.1,6.6Hz,0.6H),5.36–5.20(m,1.4H),4.33–4.25(m,2H),4.21–4.10(m,3H),2.78–2.61(m,7H),2.38–2.23(m,5H),2.06–1.96(m,1H),1.87–1.69(m,2H),1.67–1.53(m,4H),1.38–1.19(m,48H),0.88(t,J=6.9Hz,6H)。注意:部分整合反映出存在旋转异构体混合物。
ESI-HRMS:C58H89Cl2NO10Na[M+Na+]的计算值1052.5756;测定值1052.5774。
a2)((1S,4S)-4-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)(甲基)氨基甲酸1-氯乙酯(xi)
在0℃将氯甲酸1-氯乙酯(25.2μL,0.233mmol)和吡啶(35.4μL,0.438mmol)加到在CH2Cl2(5mL)中的盐酸舍曲林(50.0mg,0.146mmol)中,将该混合物在0℃搅拌30分钟,然后在室温搅拌19小时。用CH2Cl2(25mL)稀释该反应体系,用饱和NaHCO3水溶液(20mL)和盐水(20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(含有0.5% Et3N的15%乙酸乙酯/己烷),得到氨基甲酸氯乙酯xi(50.4mg,84%),为无色固体。
1H NMR(400MHz,CDCl3)δ7.34(d,J=8.3Hz,1H),7.31–7.24(m,1H),7.24–7.16(m,2H),7.13–7.04(m,1H),7.00–6.94(m,1H),6.85–6.77(m,1H),6.75–6.64(m,1H),5.54–5.46(m,0.6H),5.41–5.33(m,0.4H),4.20(br s,1H),2.74/2.71/2.70(各自s,3H),2.36–2.24(m,1H),2.09–1.97(m,1H),1.90–1.71(m,5H)。注意:部分整合和双信号反映出存在旋转异构体和非对映异构体二者。
b2)(1-((((1S,4S)-4-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)(甲基)氨基甲酰基)氧基)乙基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(2)
将1,8-二氮杂双环[5.4.0]十一-7-烯(DBU)(7.8μL,52.0μmol)加到酸-TG iii(25.0mg,37.4μmol)、氨基甲酸1-氯乙酯xi(13.4mg,32.5μmol)和碘化四丁基铵(TBAI,3.6mg,9.7μmol)在甲苯(1.2mL)中的混悬液中,将该混合物回流加热1小时。将该反应体系冷却至室温,用乙酸乙酯(30mL)稀释,用水和盐水(各20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。进行硅胶色谱法(4%-8%乙酸乙酯/甲苯),得到化合物2(19.7mg,58%),为无色油状物。
1H NMR(400MHz,CDCl3)δ7.33(d,J=8.3Hz,1H),7.31–7.16(m,3H),7.12–7.06(m,1H),6.98–6.87(m,2H),6.85–6.77(m,1H),5.51–5.43(m,0.6H),5.36–5.16(m,1.4H),4.35–4.24(m,2H),4.21–4.11(m,3H),2.77–2.56(m,7H),2.37–2.24(m,5H),2.06–1.95(m,1H),1.85–1.71(m,2H),1.65–1.49(m,7H),1.37–1.19(m,48H),0.88(t,J=6.8Hz,6H)。注意:部分整合和双信号反映出存在旋转异构体和非对映异构体二者。
ESI-HRMS:C59H91Cl2NO10Na[M+Na+]的计算值1066.5912;测定值1066.5957。
根据上述方法制得了下列包含羧基-乙缩醛或羧基-甲基乙缩醛自消除基团的化合物:
a3)((4aS,6R,7R,7aR,12bS)-3-(环丙基甲基)-6-((S)-2-羟基-3,3-二甲基丁-2-基)-7-甲氧基-1,2,3,4,5,6,7,7a-八氢-4a,7-桥亚乙基-4,12-亚甲基苯并呋喃并[3,2-e]异喹啉-9-基)碳酸氯甲酯(xi)
1H NMR(400MHz,CDCl3):δ6.88(d,J=8.2Hz,1H),6.61(d,J=8.2Hz,1H),5.88(s,1H),5.82(d,J=6.3Hz,1H),5.72(d,J=6.3Hz,1H),4.47(d,J=1.7Hz,1H),3.48(s,3H),3.06–2.98(m,2H),2.89(m,1H),2.63(dd,J=11.9,5.0Hz,1H),2.40–2.23(m,4H),2.12(t,J=9.9Hz,1H),2.03–1.79(m,3H),1.71(dd,J=12.9,2.5Hz,1H),1.35(s,3H),1.28(m,2H),1.06(m,1H),1.03(s,9H),0.81(m,1H),0.66(m,1H),0.57–0.41(m,2H),0.16–0.08(m,2H)。
b3)((((((4aS,6R,7R,7aR,12bS)-3-(环丙基甲基)-6-((S)-2-羟基-3,3-二甲基丁-2-基)-7-甲氧基-1,2,3,4,5,6,7,7a-八氢-4a,7-桥亚乙基-4,12-亚甲基苯并呋喃并[3,2-e]异喹啉-9-基)氧基)羰基)氧基)甲基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(4)
如下所述,使用上述对化合物1和2所用方法的可替代方法制得了化合物4。将碳酸银(3.1mg,11.2μmol)加到在DMF(0.6mL)中的酸-TG iii(12.9mg,19.3μmol)中,将该混合物在室温搅拌1小时。减压浓缩该反应体系,得到灰色残余物,向其中加入在甲苯(0.6mL)和TBAI(1.8mg,4.8μmol)中的碳酸氯甲酯xi(9.0mg,16.1μmol),将该混合物回流加热1.5小时。将该反应体系冷却至室温,然后用乙酸乙酯(30mL)稀释。用水(25mL)和盐水(25mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。进行硅胶色谱法(5%-15%乙酸乙酯/己烷),得到化合物4(3.7mg,19%),为无色固体。
1H NMR(400MHz,CDCl3)δ6.88(d,J=8.2Hz,1H),6.60(d,J=8.1Hz,1H),5.86(s,1H),5.82(s,2H),5.27(m,1H),4.46(s,1H),4.30(dd,J=12.0,4.3Hz,2H),4.15(dd,J=12.0,5.9Hz,2H),3.49(s,3H),3.06–2.98(m,2H),2.89(m,1H),2.73–2.60(m,5H),2.39–2.22(m,8H),2.12(t,J=9.2Hz,1H),2.01(m,1H),1.93–1.80(m,2H),1.75–1.49(m,5H),1.35(s,3H),1.34–1.20(m,49H),1.05(m,1H),1.03(s,9H),0.88(t,J=6.9Hz,6H),0.80(m,1H),0.66(m,1H),0.56–0.44(m,2H),0.16–0.09(m,2H)。
ESI-HRMS:C70H114NO14[M+H+]的计算值1192.8234;测定值1192.8244。
(1-(((((4aS,6R,7R,7aR,12bS)-3-(环丙基甲基)-6-((S)-2-羟基-3,3-二甲基丁-2-基)-7-甲氧基-1,2,3,4,5,6,7,7a-八氢-4a,7-桥亚乙基-4,12-亚甲基苯并呋喃并[3,2-e]异喹啉-9-基)氧基)羰基)氧基)乙基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(5)
1H NMR(400MHz,CDCl3)δ6.88/6.87(各自d,J=8.2Hz,1H),6.77(m,1H),6.59(d,J=8.2Hz,1H),5.89/5.88(各自s,1H),5.25(m,1H),4.46(br s,1H),4.33–4.26(m,2H),4.19–4.11(m,2H),3.49/3.48(各自s,3H),3.06–2.98(m,2H),2.89(m,1H),2.74–2.57(m,5H),2.38–2.20(m,8H),2.12(t,J=10.0Hz,1H),1.98(td,J=12.5,5.5Hz,1H),1.91–1.77(m,2H),1.70(dd,J=13.4,2.9Hz,1H),1.64–1.52(m,7H),1.35(s,3H),1.33–1.18(m,49H),1.06(m,1H),1.03(s,5H),0.88(t,J=6.9Hz,6H),0.81(m,1H),0.66(m,1H),0.55–0.43(m,2H),0.15–0.07(m,2H)。注意:双信号反映出存在非对映异构体混合物。
ESI-HRMS:C71H116NO14[M+H+]的计算值1206.8390;测定值1206.8401。
(1-(((((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊并[a]菲-17-基)氧基)羰基)氧基)乙基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(20)
1H NMR(400MHz,CDCl3)δ6.75(m,1H),5.73(s,1H),5.25(m,1H),4.53(m,1H),4.34–4.26(m,2H),4.18–4.11(m,2H),2.73–2.58(m,4H),2.48–2.15(m,9H),2.02(m,1H),1.91–1.82(m,2H),1.78–1.55(m,8H),1.521(d,J=5.4Hz,1.5H),1.517(d,J=5.4Hz,1.5H),1.47–1.20(m,52H),1.19(s,3H),1.11–0.90(m,3H),0.88(t,J=7.5Hz,6H),0.86(s,3H)。注意:双信号反映出存在非对映异构体混合物。
ESI-HRMS:C61H102O12Na[M+Na+]的计算值1049.7263;测定值1049.7273。
实施例5.通式(III)的化合物的合成,其中
R3是三甲基-锁(TML)自消除基团
a)(2-(4-((叔丁基二甲基甲硅烷基)氧基)-2-甲基丁-2-基)-3,5-二甲基苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(xiv)
将4-(二甲氨基)吡啶(DMAP,18.3mg,0.149mmol)和EDC·HCl(71.6mg,0.374mmol)加到酸-TG iii(100mg,0.149mmol)和苯酚xiii(53.0mg,0.164mmol)在CH2Cl2(4mL)中的溶液中,将该混合物在室温搅拌19小时。用CH2Cl2(10mL)稀释该反应体系,加入硅胶,减压浓缩该混合物。通过硅胶色谱法纯化(3%-7.5%乙酸乙酯/己烷),得到TML甘油三酯xiv(84.6mg,58%),为无色油状物。
1H NMR(400MHz,CDCl3)δ6.80(d,J=2.0Hz,1H),6.55(d,J=1.9Hz,1H),5.29(m,1H),4.31(dd,J=11.9,4.4Hz,2H),4.16(dd,J=12.0,5.8Hz,2H),3.51–3.44(m,2H),2.85(t,J=6.9Hz,2H),2.75(t,J=6.9Hz,2H),2.51(s,3H),2.30(t,J=7.6Hz,4H),2.22(s,3H),2.06–1.99(m,2H),1.65–1.56(m,4H),1.46(s,6H),1.37–1.20(m,48H),0.88(t,J=6.9Hz,6H),0.84(s,9H),–0.03(s,6H)。
b)(2-(4-羟基-2-甲基丁-2-基)-3,5-二甲基苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(xv)
将10-樟脑磺酸(3.0mg,12.9μmol)加到在CH2Cl2(1mL)和MeOH(1mL)中的TBS醚xiv(83.7mg,86.0μmol)中,将该混合物在室温搅拌1小时。用水(10mL)稀释该反应体系,用CH2Cl2(3×10mL)萃取水层。用饱和水溶液NaHCO3和盐水(各15mL)洗涤合并的有机萃取物,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(15%-25%乙酸乙酯/己烷),得到醇xv(59.9mg,81%),为无色油状物。
1H NMR(400MHz,CDCl3)δ6.81(d,J=2.0Hz,1H),6.56(d,J=1.4Hz,1H),5.28(m,1H),4.30(dd,J=12.0,4.4Hz,2H),4.17(dd,J=12.0,5.8Hz,2H),3.51(t,J=6.8Hz,2H),2.88(t,J=6.6Hz,2H),2.75(t,J=6.6Hz,2H),2.52(s,3H),2.29(t,J=7.6Hz,4H),2.22(s,3H),2.05(t,J=7.4Hz,2H),1.65–1.57(m,4H),1.50(s,6H),1.37–1.20(m,48H),0.88(t,J=6.9Hz,6H)。
c)(3,5-二甲基-2-(2-甲基-4-氧代丁-2-基)苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(xvi)
在0℃将氯铬酸吡啶(PCC,30.1mg,0.139mmol)加到醇xv(59.9mg,0.0697mmol)和C盐(30mg)在CH2Cl2(3mL)中的混悬液中,将该混合物在室温搅拌2小时。通过短硅胶垫过滤该反应体系,用50%乙酸乙酯/己烷洗脱,减压浓缩滤液,得到粗制醛xvi(59.8mg,定量),为黄色油状物,未经纯化使用它。
1H NMR(400MHz,CDCl3)δ9.54(t,J=2.6Hz,1H),6.84(d,J=2.0Hz,1H),6.60(d,J=1.4Hz,1H),5.28(m,1H),4.30(dd,J=12.0,4.3Hz,2H),4.16(dd,J=12.0,5.8Hz,2H),2.86(t,J=6.7Hz,2H),2.83(d,J=2.6Hz,2H),2.75(t,J=6.3Hz,2H),2.53(s,3H),2.30(t,J=7.6Hz,4H),2.23(s,3H),1.64–1.58(m,4H),1.56(s,3H),1.55(s,3H),1.32–1.22(m,48H),0.88(t,J=6.9Hz,6H)。
d)1,3-(2-((4-((1,3-双(棕榈酰氧基)丙-2-基)氧基)-4-氧代丁酰基)氧基)-4,6-二甲基苯基)-3-甲基丁酸(xvii)
将高锰酸钾(12.2mg,76.7μmol)加到在丙酮(2.4mL)和水(0.8mL)中的醛xvi(59.8mg,69.7μmol)中,将该混合物在室温搅拌17小时。用水(10mL)稀释该反应体系,用1MHCl酸化至pH 2,用CH2Cl2(3×15mL)萃取水层。用盐水(30mL)洗涤合并的有机萃取物,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(10%-25%乙酸乙酯/己烷),得到酸xvii(30.4mg,50%),为无色固体。
1H NMR(400MHz,CDCl3)δ6.81(d,J=1.6Hz,1H),6.58(d,J=1.4Hz,1H),5.28(m,1H),4.30(dd,J=11.9,4.4Hz,2H),4.16(dd,J=12.0,5.8Hz,2H),2.88(t,J=6.6Hz,2H),2.84(s,2H),2.75(t,J=6.6Hz,2H),2.53(s,3H),2.29(t,J=7.6Hz,4H),2.22(s,3H),1.64–1.58(m,4H),1.57(s,6H),1.34–1.20(m,48H),0.88(t,J=6.8Hz,6H)。
e)(2-(4-(((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊并[a]菲-17-基)氧基)-2-甲基-4-氧代丁-2-基)-3,5-二甲基苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(15)
将4-(二甲氨基)吡啶(DMAP,4.1mg,33.2μmol)、EDC·HCl(16.0mg,83.0μmol)和睾酮(17.2mg,60.0μmol)加到酸xvii(29.0mg,33.2μmol)在CH2Cl2(1.2mL)中的溶液中,将该混合物在室温搅拌19小时。用CH2Cl2(5mL)稀释该反应体系,加入硅胶,减压浓缩该混合物。通过硅胶色谱法纯化(12.5%-20%乙酸乙酯/己烷),得到化合物15(15.0mg,40%),为无色固体。
1H NMR(400MHz,CDCl3)δ6.80(d,J=2.0Hz,1H),6.57(d,J=1.9Hz,1H),5.72(s,1H),5.28(m,1H),4.46(dd,J=9.1,7.3Hz,1H),4.31(dd,J=11.9,4.4Hz,2H),4.16(dd,J=11.9,5.8Hz,2H),2.88(t,J=6.7Hz,2H),2.81(d,J=11.4Hz,2H),2.76(t,J=6.9Hz,2H),2.54(s,3H),2.50–2.23(m,8H),2.21(s,3H),2.14–1.96(m,2H),1.81(m,1H),1.69(m,1H),1.65–1.47(m,14H),1.40–1.20(m,51H),1.17(s,3H),1.10–0.92(m,4H),0.88(t,J=6.9Hz,6H),0.66(s,3H)。
ESI-HRMS:C71H115O11[M+H+]的计算值1143.8434;测定值1143.8443。
根据上述方法制得了下列包含三甲基-锁自消除基团的化合物:
(2-(4-(((1S,4S)-4-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)(甲基)氨基)-2-甲基-4-氧代丁-2-基)-3,5-二甲基苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(3)
将4-(二甲氨基)吡啶(DMAP,2.8mg,22.9μmol)、EDC·HCl(11.0mg,57.3μmol)和三乙胺(8.0μL,57.3μmol)加到盐酸舍曲林(10.2mg,29.8μmol)和酸xvii(20.0mg,22.9μmol)在CH2Cl2(1mL)中的溶液中,将该混合物在室温搅拌16小时。用CH2Cl2(5mL)稀释该反应体系,加入硅胶,减压浓缩该混合物。通过硅胶色谱法纯化(15%-25%乙酸乙酯/己烷),得到化合物3(22.2mg,83%),为无色固体。
1H NMR(400MHz,CDCl3)δ7.32(d,J=8.3Hz,0.7H),7.31(d,J=8.3Hz,0.3H),7.25–7.11(m,2H),7.08–7.02(m,1.3H),6.97–6.85(m,1.7H),6.83–6.79(m,1.7H),6.73(dd,J=8.3,2.0Hz,0.3H),6.60(d,J=1.8Hz,0.7H),6.57(d,J=1.7Hz,0.3H),5.88(dd,J=10.5,6.3Hz,0.7H),5.24(m,1H),4.96(dd,J=10.9,5.7Hz,0.3H),4.32–4.25(m,2H),4.20–4.10(m,3H),3.09(d,J=15.5Hz,0.7H),3.01(d,J=8.2Hz,0.3H),2.92–2.73(m,4.3H),2.70–2.64(m,3H),2.60–2.56(m,3.7H),2.29(t,J=7.5Hz,4H),2.23(s,2.1H),2.21(s,0.9H),2.21(m,1H),1.95(m,1H),1.69(s,2.1H),1.66(s,0.9H),1.62(s,3H),1.70–1.52(m,6H),1.34–1.20(m,48H),0.88(t,J=6.9Hz,6H)。注意:部分整合反映出存在旋转异构体混合物。
ESI-HRMS:C69H103Cl2NO9Na[M+Na+]的计算值1182.6902;测定值1182.6904。
(2-(4-(((4aS,6R,7R,7aR,12bS)-3-(环丙基-甲基)-6-((S)-2-羟基-3,3-二甲基丁-2-基)-7-甲氧基-1,2,3,4,5,6,7,7a-八氢-4a,7-桥亚乙基-4,12-亚甲基苯并呋喃并[3,2-e]异喹啉-9-基)氧基)-2-甲基-4-氧代丁-2-基)-3,5-二甲基苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(6)
1H NMR(400MHz,CDCl3)δ6.80(d,J=1.9Hz,1H),6.61–6.57(m,2H),6.53(d,J=8.1Hz,1H),5.90(s,1H),5.28(m,1H),4.39(s,1H),4.30(dd,J=11.9,4.4Hz,2H),4.16(dd,J=11.9,5.8Hz,2H),3.37(s,3H),3.06(ABq,2H),3.01–2.81(m,5H),2.76(t,J=6.7Hz,2H),2.60(dd,J=11.6,4.8Hz,1H),2.55(s,3H),2.29(t,J=7.6Hz,4H),2.37–2.18(m,4H),2.21(s,3H),2.10(t,J=9.8Hz,1H),1.95(td,J=12.6,5.4Hz,1H),1.89–1.74(m,2H),1.71–1.51(m,11H),1.33(s,3H),1.45–1.14(m,49H),1.02(s,9H),0.88(t,J=6.9Hz,6H),0.83–0.61(m,2H),0.54–0.42(m,2H)。0.14–0.07(m,2H)。
ESI-HRMS:C81H128NO13[M+H+]的计算值1322.9380;测定值1322.9404。
实施例6.通式(III)的化合物的合成,其中
R3是对羟基苄基(PHB)羰基自消除基团
a)(4-(((叔丁基二甲基甲硅烷基)氧基)甲基)-苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(xxi)
将4-(二甲氨基)吡啶(DMAP,48.0mg,0.393mmol)和EDC·HCl(123mg,0.639mmol)加到酸-TG iii(200mg,0.300mmol)和苯酚xx(93.1mg,0.391mmol)在CH2Cl2(15mL)中的溶液中,将该混合物在室温搅拌21小时。用CH2Cl2(15mL)稀释该反应体系,加入硅胶,减压浓缩该混合物。通过硅胶色谱法纯化(5%-15%乙酸乙酯/己烷),得到PHB甘油三酯xxi(202mg,76%),为无色油状物。
1H NMR(400MHz,CDCl3)δ7.34–7.29(m,2H),7.07–7.02(m,2H),5.30(m,1H),4.72(s,2H),4.31(dd,J=12.0,4.3Hz,2H),4.16(dd,J=12.0,5.9Hz,2H),2.88(t,J=6.9Hz,2H),2.76(t,J=6.5Hz,2H),2.29(t,J=7.6Hz,4H),1.63–1.55(m,4H),1.33–1.20(m,48H),0.94(s,9H),0.88(t,J=6.9Hz,6H),0.09(s,6H)。
b)(4-(羟基甲基)苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(xxii)
将10-樟脑磺酸(8.0mg,0.0344mmol)加到在CH2Cl2(2.5mL)和MeOH(2.5mL)中的TBS醚xxi(181mg,0.203mmol)中,将该混合物在室温搅拌3.5小时。用CH2Cl2(30mL)稀释该反应体系,用饱和NaHCO3水溶液(2×20mL)和盐水(20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(10%-25%乙酸乙酯/己烷),得到醇xxii(128mg,81%),为无色固体。
1H NMR(400MHz,CDCl3)δ7.40–7.35(m,2H),7.11–7.06(m,2H),5.30(m,1H),4.69(d,J=5.9Hz,2H),4.31(dd,J=12.0,4.3Hz,2H),4.16(dd,J=12.0,5.9Hz,2H),2.92–2.86(m,2H),2.79–2.73(m,2H),2.29(t,J=7.6Hz,4H),1.64–1.55(m,4H),1.34–1.19(m,48H),0.88(t,J=6.9Hz,6H)。
c)(4-((((4-硝基苯氧基)羰基)氧基)甲基)-苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(xxiii)
在0℃将氯甲酸4-硝基苯基酯(8.4mg,41.6μmol)和吡啶(3.8μL,47.0μmol)加到在CH2Cl2(2mL)中的醇xxii(20.0mg,25.8μmol)中,将该混合物在0℃搅拌30分钟,然后在室温搅拌4.5小时。用CH2Cl2(30mL)稀释该反应体系,用饱和NaHCO3水溶液和盐水(各3×25mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(10%-20%乙酸乙酯/己烷),得到碳酸PNP酯xxiii(15.7mg,65%),为无色固体。
1H NMR(400MHz,CDCl3)δ8.31–8.25(m,2H),7.48–7.43(m,2H),7.41–7.36(m,2H),7.17–7.11(m,2H),5.29(m,1H),5.28(s,2H),4.32(dd,J=12.0,4.3Hz,2H),4.17(dd,J=12.0,5.8Hz,2H),2.93–2.87(m,2H),2.79–2.73(m,2H),2.30(t,J=7.6Hz,4H),1.63–1.51(m,4H),1.34–1.18(m,48H),0.88(t,J=6.9Hz,6H)。
d)(4-((((((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊丙[a]菲-17-基)氧基)羰基)氧基)甲基)苯基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(16)
将4-(二甲氨基)吡啶(DMAP,21.3mg,0.174mmol)和DIPEA(7.1μL,0.0406mmol)加到睾酮(48.0mg,0.166mmol)和碳酸PNP酯xxiii(127mg,0.135mmol)在CH2Cl2(10mL)中的溶液中,将该混合物在室温搅拌5天。用CH2Cl2(20mL)稀释该反应体系,用1M HCl、水和盐水(各20mL)洗涤,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(5%乙酸乙酯/甲苯),得到化合物16(20.4mg,14%),为无色固体。
1H NMR(400MHz,CDCl3)δ7.42–7.37(m,2H),7.12–7.05(m,2H),5.73(s,1H),5.29(m,1H),5.12(s,2H),4.52(t,J=8.4Hz,1H),4.31(dd,J=12.0,4.3Hz,2H),4.16(dd,J=12.0,5.9Hz,2H),2.89(t,J=6.7Hz,2H),2.76(t,J=6.7Hz,2H),2.47–2.34(m,3H),2.29(t,J=7.6Hz,4H),2.34–2.16(m,2H),2.02(m,1H),1.89–1.80(m,2H),1.74–1.53(m,8H),1.47–1.19(m,51H),1.18(s,3H),1.10–0.92(m,4H),0.88(t,J=6.9Hz,6H),0.85(s,3H)。
ESI-HRMS:C66H105O12[M+H+]的计算值1089.7601;测定值1089.7617。
实施例7.通式(III)的化合物的合成,其中
R3是翻转酯自消除(FSI)基团
a)4-溴丁酸(8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15-16,17-十四氢-1H-环戊并[a]菲-17-基酯(xxvi)
将4-(二甲氨基)吡啶(DMAP,15.5mg,0.130mmol)和DCC(43.8mg,0.210mmol)加到睾酮(29.9mg,0.100mmol)和4-溴丁酸(xxv)(21.0mg,0.130mmol)在CH2Cl2(3mL)中的溶液中,将该混合物在室温搅拌24小时。再加入0.6eq.酸、1eq.DCC、0.6eq.DMAP,将该混合物在室温再搅拌2天。用CH2Cl2(10mL)稀释该反应体系,加入硅胶,减压浓缩该混合物。通过硅胶色谱法纯化(25%乙酸乙酯/己烷),得到溴化物xxvi(26.7mg,59%),为无色固体。
1H NMR(400MHz,CDCl3)δ5.73(s,1H),4.62(dd,J=9.1,7.9Hz,1H),3.47(t,J=6.5Hz,2H),2.50(td,J=7.1,1.0Hz,2H),2.47–2.23(m,4H),2.22–2.13(m,3H),2.06–1.99(m,1H),1.85(m,1H),1.78(m,1H),1.74–1.63(m,2H),1.61–1.53(m,2H),1.52–1.32(m,3H),1.23–1.15(m,1H),1.19(s,3H)1.11–0.91(m,3H),0.83(s,3H)。
b)(4-(((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊并[a]菲-17-基)氧基)-4-氧代丁基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(17)
将1,8-二氮杂双环[5.4.0]十一-7-烯(DBU)(9.9μL,66.2μmol)加到酸-TG iii(30.9mg,46.2μmol)和溴化物xxvi(18.3mg,41.8μmol)在甲苯(1.5mL)中的混悬液中,将该混合物回流加热21小时。将该反应体系冷却至室温,然后用乙酸乙酯(20mL)稀释。用水(10mL)和盐水(10mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。进行硅胶色谱法(15%-25%乙酸乙酯/己烷),得到化合物17(21.6mg,50%),为无色固体。
1H NMR(400MHz,CDCl3)δ5.73(s,1H),5.26(m,1H),4.62(dd,J=9.1,7.9Hz,1H),4.30(dd,J=11.9,4.4Hz,2H),4.15(dd,J=11.9,5.8Hz,2H),4.13(t,J=6.5Hz,2H),2.69–2.58(m,4H),2.47–2.25(m,9H),2.19(m,1H),2.07–1.91(m,3H),1.85(m,1H),1.78(m,1H),1.75–1.45(m,9H),1.44–1.21(m,59H),1.19(s,3H),1.16–0.91(m,5H),0.88(t,J=6.9Hz,6H),0.83(s,3H)。
ESI-HRMS:C62H104O11Na[M+Na+]的计算值1047.7471;测定值1047.7460。
根据上述方法制得了下列包含翻转酯自消除基团的化合物:
(5-(((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊并[a]菲-17-基)氧基)-5-氧代戊基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(18)
1H NMR(400MHz,CDCl3)δ5.73(s,1H),5.26(m,1H),4.61(dd,J=9.1,7.9Hz,1H),4.29(dd,J=11.9,4.4Hz,2H),4.15(dd,J=11.9,5.8Hz,2H),4.10(t,J=6.0Hz,2H),2.68–2.58(m,4H),2.47–2.25(m,10H),2.18(m,1H),2.02(ddd,J=13.3,4.9,3.3Hz,1H),1.85(m,1H),1.77(m,1H),1.74–1.45(m,13H),1.44–1.21(m,50H),1.19(s,3H),1.18–0.91(m,4H),0.88(t,J=6.9Hz,6H),0.83(s,3H)。
ESI-HRMS:C63H107O11Na[M+Na+]的计算值1061.7627;测定值1061.7654。
4-(5-(((8R,9S,10R,13S,14S,17S)-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊并[a]菲-17-基)氧基)-5-氧代戊基)2-甲基琥珀酸1-(1,3-双(棕榈酰氧基)丙-2-基)酯(19)
1H NMR(400MHz,CDCl3)δ5.73(s,1H),5.26(m,1H),4.61(dd,J=9.1,7.9Hz,1H),4.33–4.24(m,2H),4.21–4.04(m,4H),2.91(m,1H),2.76/2.72(各自dd,J=13.9,7.9Hz,1H),2.47–2.26(m,11H),2.18(m,1H),2.02(m,1H),1.84(m,1H),1.77(m,1H),1.74–1.44(m,13H),1.43–1.14(m,51H),1.223/1.214(各自d,J=7.2Hz,3H),1.19(s,3H),1.11–0.92(m,3H),0.88(t,J=6.9Hz,6H),0.83(s,3H)。注意:双信号反映出存在非对映异构体混合物。
ESI-HRMS:C64H109O11[M+H+]的计算值1053.7964;测定值1053.7984。
(5-(((4aS,6R,7R,7aR,12bS)-3-(环丙基甲基)-6-((S)-2-羟基-3,3-二甲基丁-2-基)-7-甲氧基-1,2,3,4,5,6,7,7a-八氢-4a,7-桥亚乙基-4,12-亚甲基苯并呋喃并[3,2-e]异喹啉-9-基)氧基)-5-氧代戊基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(7)
1H NMR(400MHz,CDCl3)δ6.77(d,J=8.1Hz,1H),6.59(d,J=8.1Hz,1H),5.88(s,1H),5.26(m,1H),4.42(d,J=1.6Hz,1H),4.29(dd,J=11.9,4.4Hz,2H),4.15(dd,J=12.0,5.8Hz,2H),4.11(t,J=6.0Hz,2H),3.45(s,3H),3.02(d,J=13.5Hz,1H),2.99(s,1H),2.88(m,1H),2.67–2.54(m,7H),2.38–2.22(m,8H),2.11(t,J=10.1Hz,1H),1.97(td,J=12.7,5.6Hz,1H),1.91–1.84(m,2H),1.82–1.68(m,5H),1.65–1.57(m,4H),1.35(s,3H),1.35–1.19(m,49H),1.05(m,1H),1.03(s,9H),0.88(t,J=6.9Hz,6H),0.84–0.76(m,1H),0.75–0.63(m,1H),0.55–0.43(m,2H),0.17–0.08(m,2H)。
ESI-HRMS:C73H120NO13[M+H+]的计算值1218.8754;测定值1218.8775。
4-(5-(((4aS,6R,7R,7aR,12bS)-3-(环丙基甲基)-6-((S)-2-羟基-3,3-二甲基丁-2-基)-7-甲氧基-1,2,3,4,5,6,7,7a-八氢-4a,7-桥亚乙基-4,12-亚甲基苯并呋喃并[3,2-e]异喹啉-9-基)氧基)-5-氧代戊基)2-甲基琥珀酸1-(1,3-双(棕榈酰氧基)丙-2-基)酯(8)
1H NMR(400MHz,CDCl3)δ6.77(d,J=8.1Hz,1H),6.59(d,J=8.1Hz,1H),5.88(s,1H),5.26(m,1H),4.42(d,J=1.5Hz,1H),4.32–4.24(m,2H),4.20–4.06(m,4H),3.45(s,3H),3.02(d,J=13.3Hz,1H),2.99(s,1H),2.96–2.84(m,2H),2.74(ddd,J=16.6,13.4,8.0Hz,1H),2.66–2.53(m,3H),2.46–2.21(m,9H),2.11(t,J=9.9Hz,1H),1.97(td,J=12.5,5.6Hz,1H),1.92–1.67(m,7H),1.65–1.56(m,4H),1.35(s,3H),1.34–1.17(m,49H),1.222(d,J=7.2Hz,1.5H),1.116(d,J=7.2Hz,1.5H),1.05(m,1H),1.03(s,9H),0.88(t,J=6.8Hz,6H),0.80(m,1H),0.67(m,1H),0.55–0.42(m,2H),0.15–0.08(m,2H)。
ESI-HRMS:C74H122NO13[M+H+]的计算值1232.8911;测定值1232.8925。
(5-((1-(异丙基氨基)-3-(4-(2-甲氧基乙基)-苯氧基)丙-2-基)氧基)-5-氧代戊基)琥珀酸1,3-双(棕榈酰氧基)丙-2-基酯(9)
在0℃将三氟乙酸(TFA,6.1μL,82.2μmol)加到在CH2Cl2(1.2mL)中的Boc-保护的前药xxvii(9.2mg,8.2μmol)中,将该混合物在室温搅拌21小时。在N2气流中浓缩该反应体系,得到粗制产物。进行硅胶色谱法(1%-3.5%甲醇/CH2Cl2),得到化合物9(6.8mg,81%),为淡黄色油状物。
1H NMR(400MHz,CDCl3)δ7.13(d,J=8.6Hz,2H),6.84–6.77(m,2H),5.38(m,1H),5.24(m,1H),4.28(dd,J=11.9,4.5Hz,2H),4.18–4.10(m,4H),4.06(t,J=5.7Hz,2H),3.55(t,J=7.0Hz,2H),3.34(s,3H),3.38–3.24(m,3H),2.81(t,J=7.0Hz,2H),2.66–2.56(m,4H),2.48–2.35(m,2H),2.31(t,J=7.6Hz,4H),1.69–1.54(m,8H),1.32(d,J=6.4Hz,6H),1.37–1.19(m,48H),0.88(t,J=6.9Hz,6H)。
ESI-HRMS:C59H104NO12[M+H+]的计算值1018.7553;测定值1018.7568。
实施例8.通式(IV)的化合物的合成,其中药用物质是麦考酚酸(MPA)
a)5-(氯甲基)3-甲基戊二酸1-(1,3-双(棕榈酰氧基)丙-2-基)酯(xviii)
将酸-TG iii(75.0mg,0.108mmol)、N,N-二甲基甲酰胺(DMF,1滴)和SOCl2(78.0μL,1.08mmol)的混合物回流加热45分钟,然后冷却至室温。减压浓缩该反应体系,然后从甲苯(各3mL)中共蒸发3次,减压干燥。将得到的酰氯再溶于CH2Cl2(1mL),滴加到在CH2Cl2(0.5mL)中的无水ZrCl4(25.1mg,0.108mmol)中,在室温搅拌15分钟,然后冷却至0℃。加入1,3,5-三烷(9.7mg,0.108mmol),将该混合物在室温搅拌20小时。用CH2Cl2(15mL)稀释该反应体系,用水和盐水(各15mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(5%-12.5%乙酸乙酯/己烷),得到氯甲酯xxviii(19.2mg,24%),为黄色油状物。
1H NMR(400MHz,CDCl3)δ5.72–5.67(m,2H),5.27(m,1H),4.31(dd,J=11.9,4.2Hz,2H),4.13(dd,J=12.0,6.1Hz,2H),2.53–2.34(m,5H),2.31(t,J=7.6Hz,4H),1.67–1.53(m,4H),1.37–1.19(m,48H),1.05(d,J=6.5Hz,3H),0.88(t,J=6.9Hz,6H)。
b)3-甲基戊二酸(E)-1-(((6-(4-(烯丙氧基)-6-甲氧基-7-甲基-3-氧代-1,3-二氢异苯并呋喃-5-基)-4-甲基己-4-烯酰基)氧基)甲基)5-(1,3-双(棕榈酰氧基)丙-2-基)酯(xxxi)
将1,8-二氮杂双环[5.4.0]十一-7-烯(DBU)(6.9μL,45.9μmol)加到MPA(OAll)xxx(12.9mg,35.7μmol)和氯甲基酯xxviii(19.0mg,25.5μmol)和TBAI(4.7mg,12.7μmol)在甲苯(0.8mL)中的混悬液中,将该混合物在80℃加热2小时。将该反应体系冷却至室温,然后用乙酸乙酯(20mL)稀释。用水和盐水(各20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。进行硅胶色谱法(15%-20%乙酸乙酯/己烷),得到被保护的前药xxxi(16.7mg,61%),为无色固体。
1H NMR(400MHz,CDCl3)δ6.09(m,1H),5.69(s,2H),5.36(m,1H),5.31–5.22(m,2H),5.18(td,J=6.7,1.2Hz,1H),5.13(s,2H),4.78(dt,J=5.9,1.2Hz,2H),4.292/4.288(各自dd,J=11.9,4.3Hz,2H),4.13(dd,J=11.9,5.9Hz,2H),3.76(s,3H),3.41(d,J=6.7Hz,2H),2.50–2.37(m,5H),2.34–2.23(m,8H),2.18(s,3H),1.77(s,3H),1.64–1.56(m,4H),1.35–1.18(m,48H),1.02(d,J=6.4Hz,3H),0.87(t,J=6.9Hz,6H)。注意:双信号反映出存在非对映异构体混合物。
c)3-甲基-戊二酸(E)-1-(1,3-双(棕榈酰氧基)丙-2-基)5-(((6-(4-羟基-6-甲氧基-7-甲基-3-氧代-1,3-二氢异苯并呋喃-5-基)-4-甲基己-4-烯酰基)氧基)甲基)酯(10)
将1,3-二甲基巴比妥酸(4.9mg,31.2μmol)和Pd(PPh3)4(5.4mg,4.7μmol)加到在CH2Cl2(0.5mL)中的烯丙基醚xxxi(16.7mg,15.6μmol)中,将该混合物在室温搅拌2小时。将该反应混合物直接上短硅胶垫,用50%乙酸乙酯/己烷洗脱。减压浓缩洗脱液,得到粗制产物,通过硅胶色谱法纯化(5%-10%乙酸乙酯/甲苯),得到化合物10(10.1mg,63%),为无色固体。
1H NMR(400MHz,CDCl3)δ7.68(s,1H),5.70(s,2H),5.30–5.21(m,2H),5.20(s,2H),4.296/4.291(各自dd,J=11.9,4.3Hz,2H),4.13(dd,J=11.9,6.0Hz,2H),3.76(s,3H),3.38(d,J=6.9Hz,2H),2.49–2.38(m,5H),2.34–2.25(m,8H),2.15(s,3H),1.79(s,3H),1.66–1.54(m,4H),1.35–1.19(m,48H),1.02(d,J=6.4Hz,3H),0.88(t,J=6.9Hz,6H)。注意:双信号反映出存在非对映异构体混合物。
ESI-HRMS:C59H97O14[M+H+]的计算值1029.6873;测定值1029.6890。
根据上述方法制得了下列通式(IV)的化合物:
a2)3-甲基戊二酸1-(1,3-双(棕榈酰氧基)丙-2-基)5-(1-氯乙基)酯(xxviii)
将酸-TG iii(120mg,0.172mmol)、N,N-二甲基甲酰胺(DMF,1滴)和SOCl2(125μL,1.72mmol)的混合物回流加热1.25小时,然后冷却至室温。减压浓缩该反应体系,然后从甲苯中共蒸发3次(各3mL),减压干燥。将得到的酰氯再溶于CH2Cl2(1.5mL),在0℃滴加到在CH2Cl2(0.5mL)中的无水ZnCl2(23.5mg,0.172mmol),在0℃搅拌5分钟。加入三聚乙醛(45.6μL,0.344mmol),将该混合物在0℃搅拌10分钟,在室温搅拌1小时。用CH2Cl2(20mL)稀释该反应体系,用水和盐水(各20mL)洗涤有机相,干燥(MgSO4),减压浓缩,得到粗制产物。通过硅胶色谱法纯化(5%-15%乙酸乙酯/己烷),得到1-氯乙基酯xxviii(14.9mg,11%),为黄色油状物。
b2)3-甲基戊二酸(E)-1-(1,3-双(棕榈酰氧基)丙-2-基)5-(1-((6-(4-羟基-6-甲氧基-7-甲基-3-氧代-1,3-二氢异苯并呋喃-5-基)-4-甲基己-4-烯酰基)氧基)乙基)酯(11)
1H NMR(401MHz,CDCl3)δ7.68(s,1H),6.80(q,J=5.4Hz,1H),5.29–5.21(m,2H),5.20(s,2H),4.32–4.26(m,2H),4.132/4.127(各自dd,J=11.9,6.0Hz,2H),3.76(s,3H),3.38(d,J=6.9Hz,2H),2.48–2.35(m,5H),2.32–2.18(m,8H),2.15(s,3H),1.79(s,3H),1.64–1.54(m,4H),1.41(d,J=5.4Hz,3H),1.36–1.18(m,48H),1.01(d,J=6.4Hz,3H),0.88(t,J=6.9Hz,6H)。注意:双信号反映出存在非对映异构体混合物。
ESI-HRMS:C60H99O14Na[M+Na+]的计算值1065.6849;测定值1065.6879。
实施例9.大鼠中的淋巴转运研究
为了评价本发明的化合物在大鼠中的淋巴转运,给大鼠肠系膜***插套管以允许连续采集肠系膜淋巴。然后将包含目标化合物的脂质制剂施用于动物,采集淋巴,随后对淋巴中的药物浓度定量。
如先前所述制备了本发明的化合物或对照化合物的基于脂质的制剂(Trevaskis,N.L.等人,Pharmaceutical Research,2005,22(11),1863-1870)。简言之,将约2mg的化合物(化合物19:1.5mg,且化合物6和7:0.05mg)、40mg油酸和25mg吐温80在玻璃小瓶中混合,直到平衡(适度加热(低于50℃)可以短期应用)。随后将由5.6mL(磷酸盐缓冲盐水(PBS,pH7.4)组成的水相加到脂质相中,通过在室温下用超声处理机超声处理乳化该制剂2分钟,所述超声处理机安装有以240μm振幅和20kHz频率运行的3.2毫米微探头尖。使用HPLC-MS-MS验证全部制剂中的化合物浓度。
选择雄性Sprague-Dawley(SD)大鼠用于淋巴转运研究,其中药用物质为麦考酚酸(MPA)、舍曲林(SER)或丁丙诺啡(BUP)。选择雌性SD大鼠用于其中睾酮为药用物质的研究。这是消除雄性大鼠中相对高和可变水平的内源性睾酮,它干扰外源性施用的睾酮的定量。将大鼠(220-320g)维持以标准膳食并且禁食过夜,可以自由引水,然后进行实验。在37℃将麻醉的大鼠置于加热垫上,如先前所述(Edwards等人Advanced Drug Delivery Reviews2001,50(1),45-60),将套管***十二指肠(用于制剂施用和再水化)、肠系膜***(用于淋巴采集)和颈动脉(用于采血)。术后,将大鼠通过以2.8毫升/小时十二指肠输注生理盐水再水化0.5小时。将脂质制剂以2.8毫升/小时输注入十二指肠2小时,此后,将输注改变为2.8毫升/小时生理盐水,用于其余的实验。将淋巴连续采集直到8小时,进入预先称重的包含10微升的1,000IU/mL肝素的埃彭道夫管。每小时变换1次采集管,通过重量分析法测定淋巴流量。将每小时的淋巴样品的等分试样储存在-80℃,然后测定。
将淋巴中的药物浓度表示为总药物且其包括游离药物以及与不同甘油酯结合的药物。通过水解淋巴(以从任意再酯化的甘油酯中释放药物)测定,然后评价游离药物。
根据收集的淋巴体积和淋巴中测定的浓度的乘积,计算在每小时收集期间化合物向淋巴中的转运。
如图1和表4所示,具有乙缩醛自消除基团(ASI)的化合物12、具有三甲基-锁(TML)自消除基团的化合物15和具有(4-碳)翻转酯自消除基团(FSI-4)的化合物17的淋巴转运分别为(所施用剂量)的1.9%、3.2%和5.2%。这低于直链对应物睾酮琥珀酸-TG(化合物21,13.4%),其中化合物12降低至目前市售的睾酮前药十一烷酸睾酮(TU)的水平。含有自消除基团的前药的淋巴转运的减少可能是由于单酸甘油酯形式的前药在胃肠道中的稳定性差(如以下实施例11中所述和图9中所示),或可能是由于单酸甘油酯形式在肠细胞中的再酯化效率降低。化合物21、化合物12和化合物17的单酸甘油酯形式的稳定性次序(即化合物21-单酸甘油酯>化合物17-单酸甘油酯>化合物12-单酸甘油酯)与这三种前药的淋巴转运的排序一致(即化合物21>化合物17>化合物12)。
在甘油酯单元的α碳或β碳位上包含甲基增加了前药的单酸甘油酯中间体的稳定性。例如,为了解决化合物12的稳定性问题,在化合物中包含甲基保护基团以形成化合物13和14(该化合物以化合物13和14的混合物形式使用)。正如从图1和表4中显见的,与化合物12相比,包含甲基保护基团显著增强了化合物13和14的淋巴转运。这与GI消化条件下增加的稳定性一致(参见图9)。化合物19(包含带有甲基支链的5-碳翻转酯自消除基团[FSI-5])的淋巴转运为(所施用剂量的)9.6%。这也高于类似的化合物,即化合物17(包含FSI-4自消除基团)但缺乏甲基。
表4.十二指肠内输注给麻醉的肠系膜***插管的大鼠后总化合物的淋巴转运(所施用剂量的%)(当n≥3时,数据表示为平均值±SEM,或当n=2时,数据表示为平均值±范围)。
*睾酮在淋巴样品中的浓度低于定量极限。
正如图4和表5中所示,具有TML自消除基团的化合物3的淋巴转运为(所施用剂量的)21.5%。与之形成鲜明对比的是,母体药物SER.HCl施用后母体药物舍曲林(SER)的淋巴转运仅为(所施用剂量的)0.05%。
表5.十二指肠内输注给麻醉的肠系膜***插管的大鼠后总化合物的淋巴转运(所施用剂量的%)(当n≥3时,数据表示为平均值±SEM,或当n=1时,数据表示为单个值)。
正如图6和表4中所示,具有TML自消除基团的化合物6和具有(5-碳)翻转酯自消除团(FSI-5)的化合物7的淋巴转运为(所施用剂量的)10.8%和24.5%。相反,BUP施用后母体药物丁丙诺啡(BUP)的淋巴转运仅为(所施用剂量的)0.01%。
表6.十二指肠内输注给麻醉的肠系膜***插管的大鼠后总化合物的淋巴转运(所施用剂量的%)(当n≥3时,数据表示为平均值±SEM,或当n=2时,数据表示为平均值±范围)。
/>
正如图8和表7中所示,具有乙缩醛自消除(ASI)基团的化合物10和具有甲基乙缩醛自消除(MASI)基团的化合物11的淋巴转运为(所施用剂量的)0.35%和1.22%。与之形成鲜明对比的是,母体药物MPA施用后母体药物麦考酚酸(MPA)的淋巴转运仅为(所施用剂量的)0.17%。
表7.十二指肠内输注给麻醉的肠系膜***插管的大鼠后总化合物的淋巴转运(所施用剂量的%)(当n≥3时,数据表示为平均值±SEM,或当n=2时,数据表示为平均值±范围)。
实施例10.大鼠中的药物动力学(PK)研究
为了评价本发明化合物的口服生物利用度,使用以下方法进行药物动力学研究。施用前一天,麻醉雌性(用于睾酮相关研究)或雄性(用于SER和BUP相关研究)Sprague-Dawley大鼠(220-320g),并且给颈动脉插管。然后允许大鼠恢复意识并禁食过夜,然后开始实验,可随意饮水。第二天早上,通过经口灌胃施用含有母体化合物或前药的制剂,并且在施用后-5分钟至24小时从颈动脉插管收集血样,并以5000rpm离心5分钟以分离血浆。在血样采集期间,大鼠可自由饮水,但在给药后再保持禁食8小时。在通过HPLC-MS-MS分析之前,将血浆样品储存在-80℃。在这种情况下,分析样品的游离药物(即非甘油酯结合的药物),并且在分析之前不水解(如淋巴样品的情况)。因此该数据反映了被运输到淋巴中且然后从体循环中的再酯化的药物-甘油酯复合物释放的药物。
如先前所述,在药用物质睾酮和甘油酯单元之间使用短连接基的甘油三酯前药(例如琥珀酸,化合物21)受到体循环中药物不良释放的限制(参见Scriba,G.K.E.,Arch.Pharm.(Weinheim)。1995,328,(3),271-276;以及Scriba,G.K.E.等人,J.Pharm.Pharmacol.1995,47,(11),945-948))。如下图2和表8所示,将自消除基团添加到连接基上增加了药用物质的***暴露,从而避免了活性剂的首过代谢,并增加了其口服生物利用度,即使当与先前弃用的琥珀酸连接基组合时也是如此。
图2示例了对有意识的颈动脉插套管的雌性SD大鼠经口管饲睾酮后剂量归一化睾酮血浆浓度。制剂含有1mg TU或TST,或约2mg本发明化合物,含有分散于40mg油酸、25mg吐温80和2ml PBS中的睾酮。将剂量归一化2mg/kg相当剂量的睾酮。数据显示为平均值±SEM。嵌入式图是棒形图形式的剂量归一化血浆AUC0-24h(nmol×h/L)睾酮的图。
表8显示经口施用化合物12-20或21后,母体睾酮的药物动力学参数。在短链连接基中不含甲基的所有情况下(化合物12、15-18或20),睾酮的***暴露大于化合物21的***暴露(约~1.4–18倍增加)或商业产品TU的***暴露(~4–54倍增加)。尽管化合物12和化合物17的淋巴转运相对低(图1和表4),但经口施用两种前药后,母体睾酮的***暴露仍然高很多。这表明,所述的自消除基团促进前药在体循环中转化为母体药物。
表8.给有意识的颈动脉插套管的SD雌性大鼠经口施用所述化合物后的药物动力学参数(将剂量归一化为2mg/kg相当的睾酮剂量且将数据表示为平均值±SEM)。
前药的实用性可通过增加前药的淋巴运输得到进一步增强。将甲基包含在短链连接基任一末端上的酯的α碳或β碳位上能够增加前药的单酸甘油酯中间体的稳定性,从而增加淋巴转运。化合物12对比化合物13/14的体外消化和淋巴转运结果(参见图9、图1和表4)支持该启示,并显示在模拟肠道条件下化合物13/14显著增强的稳定性。与化合物13/14的淋巴运输增加以及自消除基团促进睾酮从前药***释放的潜力一致,单独施用化合物13/14或化合物13后睾酮的***暴露比化合物12高~13倍,比TU高95-97倍(表8)。此外,在FSI前药的情况下,将甲基包含在短链连接基上还提高了睾酮的生物利用度。因此,化合物19施用后睾酮的***暴露比化合物18高1.9倍,比TU高105倍(表8)。
图5示例对有意识的颈动脉插套管的雄性SD大鼠经口管饲制剂后剂量归一化SER血浆浓度。在SER母体药物对照组中,制剂含有溶于2ml水中的0.7mg SER.HCl。前药制剂包含2mg本发明化合物,含有分散在40mg油酸、25mg吐温80和2ml PBS中的SER。将剂量归一化为SER的2mg/kg相当剂量。数据显示为平均值±SEM。嵌入式图是棒形图形式的SER的剂量归一化血浆AUC0-24h(nmol×h/L)的图。
表9中显示了SER.HCl、化合物1、2和3施用后SER的药物动力学参数。在所有情况下,施用所述前药后SER的***暴露大于SER.HCl的***暴露(2-3倍增加)。这表明,所述的前药是通过淋巴转运的(如图4和表5中的化合物3所例证的),并且所述的自消除基团促进了前药在体循环中转化为母体药物。
表9.给有意识的颈动脉插套管的SD雄性大鼠经口施用SER相关化合物后的药物动力学参数(将剂量归一化为2mg/kg相当的SER剂量且将数据表示为平均值±SEM)。
图7示例对有意识的颈动脉插套管的雄性SD大鼠经口管饲制剂后剂量归一化BUP血浆浓度。在BUP母体药物对照组中,制剂含有溶于2ml 0.1%乙酸水溶液中的0.02mg BUP。前药制剂包含0.05mg本发明化合物,含有分散在40mg油酸、25mg吐温80和2ml PBS中的BUP。将剂量归一化为BUP的0.06mg/kg相当的剂量。数据显示为平均值±SEM。嵌入式图是棒形图形式的BUP的剂量归一化血浆AUC0-6h(nmol×h/L)的图。
表10中显示了BUP、化合物5、6和7施用后BUP的药物动力学参数。在所有情况下,施用本发明的化合物后BUP的***暴露大于BUP的***暴露(7-14倍增加)。这表明,所述的前药是通过淋巴转运的(如图6和表6中化合物6和7所例证的),并且所述的自消除基团促进了前药在体循环中转化为母体药物。
表10.给有意识的颈动脉插套管的SD雄性大鼠经口施用BUP相关化合物后的药物动力学参数(将剂量归一化为0.06mg/kg相当的BUP剂量且将数据表示为平均值±SEM)。
*使用截短的AUCs(AUC0-6h)而非AUC0-24h,这是因为在施用母体药物后BUP血浆浓度与时间关系图中存在第二个峰。第二个峰最有可能反映BUP的肠肝再循环。
实施例11.猪胰酶脂酶对化合物的体外水解
通过与猪胰脂肪酶一起温育进行睾酮前药的体外水解。简言之,在水解实验之前,将1g猪胰酶制剂分散在5ml脂解缓冲液中,制备胰脂肪酶溶液。充分混合悬浮液并在5℃以3500rpm离心15分钟以提供上清液。用0.474克tris-马来酸盐(2mM)、0.206克CaCl2.H2O(1.4mM)和8.775克NaCl(150mM)制备了1000毫升量的脂解缓冲液,用NaOH调节至pH 6.5。为了评价前药在肠中水解的可能性,将20微升前药溶液(1mg/ml溶于乙腈)、900微升模拟肠胶束溶液[用0.783克NaTDC(3mM)和0.291克磷脂酰胆碱(0.75mM)于500毫升脂解缓冲液中制备]和100微升酶溶液在37℃下温育。温育后0、5、10、15、30、60、90、120和180分钟时取出20微升温育溶液样品,并加到180微升ACN中以停止脂解。涡旋混合物并在5000rpm下离心5分钟以在分析之前沉淀蛋白质。通过HPLC-MS分析上清液中的残余化合物浓度,并分析化合物水解的潜在产物。
与消化酶一起温育时,非常迅速地形成前药的单酸甘油酯形式。因此,用初始消化过程产生的单酸甘油酯形式的稳定性更好地评价模拟肠道条件下的稳定性。单酸甘油酯形式在进入淋巴***之前必须保持完整以在肠细胞中被吸收和再酯化。图9中,将与新鲜制备的猪胰脂肪酶体外温育过程中化合物12、化合物15-17和化合物20(每组n=2-3)的单酸甘油酯形式的稳定性曲线与含有非自消除基团的化合物21的稳定性曲线(n=3)比较。数据显示,包含所述的乙缩醛(ASI)、翻转酯(FSI)、羧基(甲基乙缩醛)(CMSI)或对羟基苄基羰基(PHB)自消除基团导致前药的MG形式的管腔稳定性显著降低。然而,因为化合物15的单酸甘油酯形式与化合物21的单酸甘油酯形式类似稳定,所以三甲基锁自消除基团似乎对管腔稳定性没有影响。
图9还提供了甲基取代改善含有乙缩醛自消除连接基的睾酮前药的腔稳定性的能力的证据(其中乙缩醛基团通常降低管腔稳定性)。如该图中所示,化合物12的单酸甘油酯形式在体外脂解试验中是不稳定的。相反,α和β甲基取代的化合物13/14的混合物更稳定得多。甲基取代的ASI前药的增强稳定性最有可能是体内淋巴转运显著增加以及经口施用后体循环中睾酮暴露睾酮增加的原因。
实施例12.在补充了脂蛋白脂酶的淋巴中
MPA从前药中体外释放
为了探究淋巴***中从TG前药释放游离MPA(MPA的活性位点在淋巴***中富含的淋巴细胞中),将MPA前药与补充了脂蛋白脂肪酶(LPL,200单位/毫升)的大鼠淋巴一起温育。LPL是在正常生理条件下水解脂蛋白结合的TG所需的关键酶,因此预期它是血浆中重新酯化的药物-TG构建体的脂解的关键贡献者,主要是通过释放TG-模拟物的sn-1和sn-3位的FA来进行,然后通过酯酶水解从2'位置释放药物。LPL在生理条件下与淋巴细胞或淋巴***/血管内皮细胞连接。目前在体外研究中,因此大鼠淋巴补充了LPL以更好地反映体内情况。为了开始水解,将10微升LPL溶液(10,000单位/毫升)加到10微升前药溶液(1mg/ml溶于乙腈中)和500微升空白Sprague Dawley大鼠淋巴的混合物中。将该溶液在37℃温育。温育后0、5、10、15、30、60、90、120和180分钟取出温育溶液的样品(20微升),并加到980微升9:1(v/v)ACN-水中以终止脂解。涡旋混合物并在4500g离心5分钟以沉淀蛋白质,然后分析。通过HPLC-MS/MS分析上清液的MPA浓度。
如图10(每种前药n=1)中所示,在与LPL补充的大鼠淋巴一起温育时,从化合物10和化合物11中释放药理活性的MPA非常迅速。母体MPA从这两种含有SI基团的前药中的释放速率远高于从不含SI基团的前药MPA-TG中的释放速率。数据显示,包含乙缩醛(ASI)或甲基乙缩醛(MASI)自消除基团导致母体化合物的释放显著增强,因此提供了将治疗剂靶向递送至淋巴***中的活性位点的机会。
Claims (22)
1.式(I)的化合物,或其药学上可接受的盐:
其中
R1和R2独立地表示H或C2-C28脂肪酸的残基;
-X-选自-O-、-NH-和-S-;
表示药用物质的残基;
-L-是-OC(O)-或-X’-;
当L-是-OC(O)-时,-Y-表示任选被取代的-C1-C20烷基C(O)OCH2-、-C2-C20烯基C(O)OCH2-或-C2-C20炔基C(O)OCH2-基团;其中所述的烷基、烯基或炔基基团上的碳原子的一个或多个可以被NH、S、O、C5-C8芳族或脂族环状基团或者C5-C8芳族或脂族杂环基团替代,条件是所述烷基、烯基或炔基基团不超过相当于直链C20烷基的长度;或者
当-L-是-X’-时,-Y-表示任选被取代的-C1-C2烷基C(O)R3-基团或-C2烯基C(O)R3-或-C2炔基C(O)R3-基团;
R3是自消除基团;
X’是O、S、N(R4)或N(H)S(O)2;
R4是H或C1-C4烷基。
2.根据权利要求1的化合物,其中R3选自:
其中表示与药用物质的连接点以及与-Y-基团的连接点。
3.根据权利要求1的化合物,其表示为式(II),或其药学上可接受的盐:
其中
R1、R2和-X-如根据权利要求1中所定义;
R3是自消除基团;
表示药用物质的残基;
-L-是-X’-;
X’是O、S、N(R4)或N(H)S(O)2;
R4是H或C1-C4烷基;
R5选自氢和C1-C4烷基。
4.根据权利要求1的化合物,它表示为式(III),或其药学上可接受的盐:
其中
R1、R2和-X-如根据权利要求3中所定义;
R3是自消除基团;
表示药用物质的残基;
-L-是-X’-;
X’是O、S、N(R4)或N(H)S(O)2;
R4是H或C1-C4烷基;
R5和R6单独地选自氢和C1-C4烷基。
5.根据权利要求1的化合物,它表示为式(IV),或其药学上可接受的盐:
其中
R1、R2和-X-如根据权利要求3中所定义;
表示药用物质的残基;
R5和R6单独地选自氢和C1-C4烷基;
R7是氢或C1-C4烷基;以及
n是0-18。
6.根据权利要求1至5任一项的化合物,其中所述的药用物质是在经口施用后表现出大于50%首过代谢或具有高度可变的首过代谢的药用物质。
7.根据权利要求1至6任一项的化合物,其中所述的药用物质选自睾酮、麦考酚酸、***类(***)、阿片类(例如***)、四氢***酚、***二酚、美托洛尔、雷洛昔芬、阿法沙龙、他汀类例如阿托伐他汀、丁丙诺啡、喷他佐辛、***、L-DOPA、利多卡因、氯丙嗪、阿米替林、去甲替林、氧烯洛尔、拉贝洛尔、沙丁胺醇、环硫雄醇、美法仑或洛伐他汀。
8.根据权利要求7的化合物,其中所述的药用物质是睾酮,且所述的化合物表示为式(V)或其药学上可接受的盐:
其中R1、R2和-X-如根据权利要求1中所定义;
R5和R6单独选自氢和C1-C4烷基;以及
R3是自消除基团。
9.根据权利要求4至8任一项的化合物,其中R5是甲基,且R6是氢。
10.根据权利要求4至8任一项的化合物,其中R5是氢,且R6是甲基。
11.根据权利要求1至10任一项的化合物,其中X是氧。
12.根据权利要求1至11任一项的化合物,其中R1和R2是棕榈酸的残基。
13.治疗或预防疾病或障碍的方法,其中在所述的疾病或障碍中睾酮水平的增加是有益的,该方法包括对有此需要的受试者施用治疗有效量的根据根据权利要求8至12任一项的化合物。
14.根据权利要求13的方法,其中所述的疾病或障碍是性腺功能减退症、因骨髓衰竭导致的贫血、因肾衰竭导致的贫血、慢性呼吸衰竭、慢性心力衰竭、类固醇依赖性自身免疫疾病、艾滋病消耗、遗传性血管水肿或荨麻疹、末期乳腺癌或绝经。
15.促进药用物质的淋巴转运和***释放的方法,其包括使式(VI)的前药残基或其药学上可接受的盐与所述的药物化合物缀合:
其中
R1和R2独立地表示H或C2-C28脂肪酸的残基;
-X-选自-O-、-NH-和-S-;
-Y-表示任选被取代的-C1-C2烷基C(O)R3-基团或-C2烯基C(O)R3-或-C2炔基C(O)R3-基团;
R3是自消除基团;以及
表示连接基与所述的药物活性剂缀合的点。
16.根据权利要求15的方法,其中R3选自:
其中表示与药用物质的连接点以及与-Y-基团的连接点。
17.根据权利要求13至16任一项的方法,其中将所述的化合物与食物一起经口施用以促进转运至肠淋巴。
18.根据权利要求13至17任一项的方法,其中将所述的化合物与基于脂质的制剂一起经口共同施用以促进转运至肠淋巴。
19.根据权利要求13至16任一项的方法,其中将所述的化合物与酶抑制剂经口共同施用。
20.根据权利要求1至5任一项的化合物,其中所述的化合物被选择以促进所述的药用物质在淋巴***内靶向递送。
21.根据权利要求20的化合物,其中所述的药用物质选自非甾类抗炎药物(NSAIDS,例如阿司匹林、布洛芬、萘普生)、COX-2抑制剂(例如塞来昔布)、皮质类固醇抗炎药物(例如***龙、***)、抗疟疾药物(例如羟氯喹)、亚硝基脲类、甲氨蝶呤、更生霉素、蒽环类(例如柔红霉素)、丝裂霉素C、博来霉素、光辉霉素、作用于抑免蛋白的药物(例如环孢素、他克莫司、西罗莫司)、柳氮磺吡啶、来氟米特、麦考酚酸酯、阿片样物质、芬戈莫德、多球壳菌素、苯丁酸氮芥、多柔比星、奈拉滨、可的松、***、***、普拉曲沙、长春碱、硼替佐米、奈拉滨、盐酸柔红霉素、氯法拉滨、阿糖胞苷、达沙替尼、甲磺酸伊马替尼、盐酸普纳替尼、硫酸长春新碱、盐酸苯达莫司汀、磷酸氟达拉滨、波舒替尼、尼洛替尼、美琥他辛、卡培他滨、紫杉醇、吉西他滨、氟维司群、他莫昔芬、拉帕替尼、托瑞米芬、伊沙匹隆、艾立布林、阿苯达唑、伊维菌素、乙胺嗪、阿苯达唑、多西环素、氯生太尔、马拉韦罗、恩夫韦肽、脱氧胸腺嘧啶核苷、齐多夫定、司他夫定、去羟肌苷、扎西他滨、阿巴卡韦、拉米夫定、恩曲他滨、替诺福韦、地拉韦啶、利匹韦林、拉替拉韦、艾维雷韦、洛匹那韦、茚地那韦、奈非那韦、氨普那韦、利托那韦、阿昔洛韦、免疫抑制剂例如麦考酚酸和药物活性肽类。
22.药物组合物,其包含治疗有效量的根据权利要求1至12、20或21任一项的化合物或其药学上可接受的盐,以及至少一种药学上可接受的载体或稀释剂。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015903661A AU2015903661A0 (en) | 2015-09-08 | Lymph directing prodrugs | |
AU2015903661 | 2015-09-08 | ||
PCT/AU2016/050845 WO2017041139A1 (en) | 2015-09-08 | 2016-09-08 | Lymph directing prodrugs |
CN201680061468.9A CN108137482B (zh) | 2015-09-08 | 2016-09-08 | 定向淋巴的前药 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680061468.9A Division CN108137482B (zh) | 2015-09-08 | 2016-09-08 | 定向淋巴的前药 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118063537A true CN118063537A (zh) | 2024-05-24 |
Family
ID=58240435
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680061468.9A Active CN108137482B (zh) | 2015-09-08 | 2016-09-08 | 定向淋巴的前药 |
CN202111142093.8A Pending CN114031658A (zh) | 2015-09-08 | 2016-09-08 | 定向淋巴的前药 |
CN202410211373.7A Pending CN118063537A (zh) | 2015-09-08 | 2016-09-08 | 定向淋巴的前药 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680061468.9A Active CN108137482B (zh) | 2015-09-08 | 2016-09-08 | 定向淋巴的前药 |
CN202111142093.8A Pending CN114031658A (zh) | 2015-09-08 | 2016-09-08 | 定向淋巴的前药 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11738087B2 (zh) |
EP (1) | EP3347340A4 (zh) |
JP (2) | JP7118888B2 (zh) |
CN (3) | CN108137482B (zh) |
AU (3) | AU2016318229A1 (zh) |
CA (1) | CA2997106C (zh) |
WO (1) | WO2017041139A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3180349A4 (en) | 2014-08-12 | 2018-08-22 | Monash University | Lymph directing prodrugs |
JP7118888B2 (ja) | 2015-09-08 | 2022-08-16 | モナッシュ ユニバーシティ | リンパ指向性プロドラッグ |
EP3674289B9 (en) * | 2017-08-25 | 2023-12-13 | Guangzhou Henovcom Bioscience Co., Ltd | Long-acting rasagiline prodrug, preparation method and use thereof |
US11883497B2 (en) * | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
EP3675838A4 (en) * | 2017-08-29 | 2021-04-21 | PureTech LYT, Inc. | LIPID PRODUCTS DIRECTED TO THE LYMPHATIC SYSTEM |
JP6826014B2 (ja) * | 2017-09-13 | 2021-02-03 | 株式会社東芝 | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット |
EP3724164A1 (en) * | 2017-12-11 | 2020-10-21 | GlaxoSmithKline Intellectual Property Development Ltd | Modulators of indoleamine 2,3-dioxygenase |
WO2019126378A1 (en) | 2017-12-19 | 2019-06-27 | Ariya Therapeutics, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
WO2019126374A1 (en) * | 2017-12-19 | 2019-06-27 | Ariya Therapeutics, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
CA3107481A1 (en) * | 2018-08-02 | 2020-02-06 | Puretech Lyt, Inc. | Lipid prodrugs of pregnane neurosteroids and uses thereof |
CN109851593B (zh) * | 2019-02-01 | 2021-04-16 | 沈阳药科大学 | 基于淋巴介导转运的甘油三酯前药及其制备方法 |
CA3131977C (en) * | 2019-03-22 | 2022-04-26 | Integrated Nanotherapeutics Inc. | Lipid conjugate prepared from scaffold moiety |
CN110201181B (zh) * | 2019-06-19 | 2020-12-25 | 湖南师范大学 | 共同负载洛伐他汀和多柔比星的普鲁兰纳米粒子及其制备方法 |
WO2021051172A1 (en) * | 2019-09-19 | 2021-03-25 | Monash University | Lipid prodrugs of celecoxib and uses thereof |
IL295362A (en) * | 2020-02-05 | 2022-10-01 | Puretech Lyt Inc | Lipid drug inhibitors of neurosteroids |
CN111892485A (zh) * | 2020-06-25 | 2020-11-06 | 黑龙江纳贝斯抗冠素生物科技有限公司 | 一种从工业***中提取***二酚(cbd)的新方法 |
EP4232091A1 (en) * | 2020-10-26 | 2023-08-30 | Monash University | Lymph-targeting formulations |
CN116981454A (zh) * | 2021-03-26 | 2023-10-31 | 日清奥利友集团株式会社 | 血中癸酸浓度的上升方法、血中癸酸浓度上升剂、医药组合物、食品组合物 |
WO2022235587A1 (en) * | 2021-05-03 | 2022-11-10 | Terran Biosciences Inc. | Lipid prodrugs of tryptamine and phenethylamine psychedelics and uses thereof |
CA3225133A1 (en) | 2021-07-07 | 2023-01-12 | Matthew Alexander James Duncton | N,n-dimethyltryptamine and related psychedlics and uses thereof |
WO2023103929A1 (zh) * | 2021-12-06 | 2023-06-15 | 江苏亚虹医药科技股份有限公司 | 氟维司群衍生物及其制备方法和医药用途 |
WO2023183795A1 (en) * | 2022-03-22 | 2023-09-28 | Elysium Therapeutics, Inc. | Opioid antagonist prodrugs and formulations for the reversal of opioid overdoses |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8313634D0 (en) | 1982-06-18 | 1983-06-22 | Ici Plc | Halogenophenyl glyceride esters |
DE3834132A1 (de) | 1988-10-07 | 1990-04-12 | Knoll Ag | Hydroxypropafenonglyceride |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
ATE286884T1 (de) | 1996-03-28 | 2005-01-15 | Shionogi & Co | Durch lymphe absorbierbare imidazolderivate |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
DE60007552T2 (de) | 1999-12-10 | 2004-09-23 | Pfizer Products Inc., Groton | PYRROLO[2,3-d]PYRIMIDIN-VERBINDUNGEN ALS PROTEIN KINASEN HEMMER |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
JP4324343B2 (ja) | 2001-04-24 | 2009-09-02 | 富士フイルム株式会社 | トリヨードフェニル基及びステロイド残基を有する化合物 |
JP3836436B2 (ja) | 2001-04-27 | 2006-10-25 | 全薬工業株式会社 | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
DK1536827T3 (da) | 2002-08-14 | 2009-04-20 | Silence Therapeutics Ag | Anvendelse af proteinkinase N-beta |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
MXPA05012799A (es) | 2003-05-30 | 2006-02-22 | Gemin X Biotechnologies Inc | Compuestos triheterociclicos, composiciones y metodos para tratar cancer o enfermedades virales. |
CN101961497A (zh) | 2003-07-03 | 2011-02-02 | 宾夕法尼亚大学理事会 | 对Syk激酶表达的抑制 |
WO2005038009A2 (en) | 2003-10-17 | 2005-04-28 | Ranbaxy Laboratories Limited | Production of tacrolimus (fk-506) using new streptomyces species |
USRE44638E1 (en) | 2004-05-13 | 2013-12-10 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
BRPI0510909A2 (pt) | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
CA2591948C (en) | 2005-01-19 | 2013-11-12 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
CA2606147C (en) | 2005-05-12 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
CN103819416A (zh) | 2005-10-07 | 2014-05-28 | 埃克塞里艾克西斯公司 | N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途 |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
SI2455382T1 (sl) | 2005-12-13 | 2017-03-31 | Incyte Holdings Corporation | S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
RU2008136574A (ru) | 2006-02-13 | 2010-03-27 | Новартис АГ (CH) | Высокая дозировка микофеноловой кислоты (мфк) |
JP5148597B2 (ja) | 2006-04-26 | 2013-02-20 | エフ.ホフマン−ラ ロシュ アーゲー | 医薬化合物 |
ES2584331T3 (es) | 2006-09-22 | 2016-09-27 | Pharmacyclics Llc | Inhibidores de tirosina cinasa de Bruton |
TW200824713A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
WO2008109943A1 (en) | 2007-03-12 | 2008-09-18 | Cytopia Research Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
KR100975520B1 (ko) | 2008-02-01 | 2010-08-12 | 종근당바이오 주식회사 | 마이코페놀레이트 모페틸의 개선된 제조방법 |
ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
MX2010012648A (es) | 2008-05-20 | 2010-12-14 | Neurogesx Inc | Analogos de acetaminofeno solubles en agua. |
US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
WO2011051967A2 (en) | 2009-10-23 | 2011-05-05 | Alkem Laboratories Ltd | Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof |
WO2011083150A2 (en) | 2010-01-07 | 2011-07-14 | Akron Molecules Gmbh | Obesity small molecules |
US20110213028A1 (en) | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid mycophenolate derivatives and their uses |
WO2011120044A1 (en) | 2010-03-26 | 2011-09-29 | Duke University | Conjugated neuroactive steroid compositions and methods of use |
AU2012233667C1 (en) | 2011-04-01 | 2017-03-02 | Sandoz Ag | Regioselective acylation of Rapamycin at the C-42 position |
CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
MX371017B (es) | 2014-02-03 | 2020-01-13 | Vitae Pharmaceuticals Llc | Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma. |
EP3180349A4 (en) * | 2014-08-12 | 2018-08-22 | Monash University | Lymph directing prodrugs |
JP7118888B2 (ja) | 2015-09-08 | 2022-08-16 | モナッシュ ユニバーシティ | リンパ指向性プロドラッグ |
AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3374369B1 (en) | 2015-11-12 | 2020-03-18 | Board of Regents of the University of Nebraska | Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof |
EP3592755A1 (en) | 2017-03-08 | 2020-01-15 | Theravance Biopharma R&D IP, LLC | Glucuronide prodrugs of tofacitinib |
EP3641779B1 (en) | 2017-06-23 | 2024-02-28 | The Board of Trustees of the University of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
EP3675838A4 (en) | 2017-08-29 | 2021-04-21 | PureTech LYT, Inc. | LIPID PRODUCTS DIRECTED TO THE LYMPHATIC SYSTEM |
US20190065544A1 (en) | 2017-08-29 | 2019-02-28 | Walmart Apollo, Llc | System and method for collaborative sharing of database information |
-
2016
- 2016-09-08 JP JP2018530942A patent/JP7118888B2/ja active Active
- 2016-09-08 WO PCT/AU2016/050845 patent/WO2017041139A1/en active Application Filing
- 2016-09-08 US US15/758,633 patent/US11738087B2/en active Active
- 2016-09-08 AU AU2016318229A patent/AU2016318229A1/en not_active Abandoned
- 2016-09-08 CN CN201680061468.9A patent/CN108137482B/zh active Active
- 2016-09-08 CA CA2997106A patent/CA2997106C/en active Active
- 2016-09-08 EP EP16843301.9A patent/EP3347340A4/en active Pending
- 2016-09-08 CN CN202111142093.8A patent/CN114031658A/zh active Pending
- 2016-09-08 CN CN202410211373.7A patent/CN118063537A/zh active Pending
-
2021
- 2021-02-16 AU AU2021200991A patent/AU2021200991C1/en active Active
-
2022
- 2022-08-03 JP JP2022124051A patent/JP2022160564A/ja active Pending
-
2023
- 2023-05-12 AU AU2023202974A patent/AU2023202974A1/en active Pending
- 2023-06-28 US US18/343,554 patent/US20240050573A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017041139A1 (en) | 2017-03-16 |
US11738087B2 (en) | 2023-08-29 |
AU2023202974A1 (en) | 2023-06-01 |
CN108137482A (zh) | 2018-06-08 |
EP3347340A1 (en) | 2018-07-18 |
CA2997106A1 (en) | 2017-03-16 |
US20240050573A1 (en) | 2024-02-15 |
CN114031658A (zh) | 2022-02-11 |
JP2018534342A (ja) | 2018-11-22 |
US20180243425A1 (en) | 2018-08-30 |
CA2997106C (en) | 2024-06-04 |
JP2022160564A (ja) | 2022-10-19 |
AU2021200991B2 (en) | 2023-02-16 |
AU2016318229A1 (en) | 2018-03-29 |
AU2021200991C1 (en) | 2023-11-16 |
AU2021200991A1 (en) | 2021-03-11 |
JP7118888B2 (ja) | 2022-08-16 |
EP3347340A4 (en) | 2019-01-23 |
CN108137482B (zh) | 2024-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108137482B (zh) | 定向淋巴的前药 | |
JP7229967B2 (ja) | リンパ指向プロドラッグ | |
KR20110036888A (ko) | 리포좀 나노입자에 사용하기 위한 변형된 약물 | |
JP2021505591A (ja) | 非アルコール性脂肪性肝炎を処置するための脂肪酸誘導体 | |
Qandil et al. | Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile | |
Lalanne et al. | Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV | |
KR20200052280A (ko) | 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |